NEWS 20 JUL 28

NEWS 22 AUG 13

AUG 01

NEWS 21

Welcome to STN International! Enter x:x LOGINID: ssspta1633cxq PASSWORD: TERMINAL (ENTER 1, 2, 3, OR ?):2 Welcome to STN International NEWS Web Page for STN Seminar Schedule - N. America NEWS 2 APR 04 STN AnaVist, Version 1, to be discontinued NEWS 3 APR 15 WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats 4 APR 28 EMBASE Controlled Term thesaurus enhanced NEWS NEWS IMSRESEARCH reloaded with enhancements 5 APR 28 6 MAY 30 NEWS INPAFAMDB now available on STN for patent family searching NEWS 7 MAY 30 DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option 8 JUN 06 EPFULL enhanced with 260,000 English abstracts NEWS JUN 06 KOREAPAT updated with 41,000 documents NEWS 9 USPATFULL and USPAT2 updated with 11-character NEWS 10 JUN 13 patent numbers for U.S. applications CAS REGISTRY includes selected substances from NEWS 11 JUN 19 web-based collections CA/CAplus and USPAT databases updated with IPC NEWS 12 JUN 25 reclassification data AEROSPACE enhanced with more than 1 million U.S. NEWS 13 JUN 30 patent records JUN 30 EMBASE, EMBAL, and LEMBASE updated with additional NEWS 14 options to display authors and affiliated organizations STN on the Web enhanced with new STN AnaVist NEWS 15 JUN 30 Assistant and BLAST plug-in STN AnaVist enhanced with database content from NEWS 16 JUN 30 EPFULL CA/CAplus patent coverage enhanced NEWS 17 JUL 28 NEWS 18 JUL 28 EPFULL enhanced with additional legal status information from the epoline Register IFICDB, IFIPAT, and IFIUDB reloaded with NEWS 19 JUL 28 enhancements

STN Viewer performance improved

INPADOCDB and INPAFAMDB coverage enhanced

CA/CAplus enhanced with printed Chemical Abstracts

page images from 1967-1998

NEWS 23 AUG 15 CAOLD to be discontinued on December 31, 2008

NEWS 24 AUG 15 CAplus currency for Korean patents enhanced

NEWS 25 AUG 25 CA/CAplus, CASREACT, and IFI and USPAT databases enhanced for more flexible patent number searching

CAS definition of basic patents expanded to ensure NEWS 26 AUG 27

comprehensive access to substance and sequence

information

NEWS EXPRESS JUNE 27 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 23 JUNE 2008.

NEWS HOURS STN Operating Hours Plus Help Desk Availability

Welcome Banner and News Items NEWS LOGIN

NEWS IPC8 For general information regarding STN implementation

of IPC 8

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* STN Columbus

FILE 'HOME' ENTERED AT 15:24:37 ON 02 SEP 2008

=> FIL BIOSIS CAPLUS EMBASE COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION

0.63

0.63

FULL ESTIMATED COST

FILE 'BIOSIS' ENTERED AT 15:26:25 ON 02 SEP 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:26:25 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:26:25 ON 02 SEP 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s mRNA (3a) instabil? sequence

19 MRNA (3A) INSTABIL? SEQUENCE L1

=> s mRNA (3a) instabil?

964 MRNA (3A) INSTABIL? L2

```
L3
             0 L1 AND APP
=> s 12 and APP
             3 L2 AND APP
L4
=> dup rem 14
PROCESSING COMPLETED FOR L4
              3 DUP REM L4 (0 DUPLICATES REMOVED)
=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 3 ANSWERS - CONTINUE? Y/(N):y
     ANSWER 1 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN
L5
AN
     2004:999715
                  CAPLUS
DN
     141:406751
     Assay and expression systems comprising reporter gene and
instability
     sequence DNA for identifying compounds which affect stability of
mRNA
     Kastelic, Tania; Cheneval, Dominique
ΙN
PA .
     Novation Pharmaceuticals Inc., Can.
     U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No.
SO
869,159.
     CODEN: USXXCO
DT
     Patent
LA
     English
FAN.CNT 2
                         KIND
                                DATE
                                            APPLICATION NO.
     PATENT NO.
DATE
                                _____
     ______
                        A1
                               20041118
                                            US 2004-814634
    US 20040231007
20040401
                       Al
                               20000706 WO 1999-CA1235
     WO 2000039314
19991223
             AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN,
CR, CU,
             CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL,
             IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU,
LV, MA,
             MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE,
SG, SI,
             SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF,
BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
```

=> s l1 and APP

```
A1
                                20051013
                                            AU 2005-229165
     AU 2005229165
20050401
     CA 2603585
                          A1
                                 20051013
                                             CA 2005-2603585
20050401
                          A1
                                 20051013
                                            WO 2005-CA491
     WO 2005095615
20050401
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,
             MR, NE, SN, TD, TG
                                 20070418 · EP 2005-730094
     EP 1774000
                          A1
20050401
             AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
         R:
HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
                                 20071101
                                             JP 2007-505349
     JP 2007530058
20050401
     US 20070190532
                          A1
                                 20070816
                                            US 2007-594851
20070504
PRAI GB 1998-28709
                           Α
                                 19981224
                          W
     WO 1999-CA1235
                                 19991223
     US 2001-869159
                          A2
                                 20010815
     US 2004-814634
                           Α
                                 20040401
     WO 2005-CA491
                           W
                                 20050401
     The present invention relates to an assay for the identification
AB
of biol.
     active compds., in particular to a reporter gene assay for the
     identification of compds., which have an effect on mRNA
```

stability. More particularly, the present invention relates to a reporter gene expression

system and cell lines comprising said expression system. The invention

further relates to compds. which destabilize mRNA. Radicicol and radicicol analog A showed a clear effect on mRNA stability. Human

APP, Bcl-2 $\alpha$ , c-myc, TNF $\alpha$ , IL-1 $\beta$ , VEGF instability sequence were constructed. Instability sequence DNA is from The gene

encoding a cytokine, a gene encoding a chemokine, a gene encoding a

nuclear transcription factor, a gene encoding an oxygenase, a
proto-oncogene, an immediate early gene, a cell cycle
controlling gene,

and a gene involved in apoptosis.

L5 ANSWER 2 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:5273 CAPLUS

DN 132:147542

TI Growth factor-mediated stabilization of amyloid precursor protein mRNA is

mediated by a conserved 29-nucleotide sequence in the 3'-untranslated

region

AU Rajagopalan, Lakshman E.; Malter, James S.

CS Department of Pathology and Laboratory Medicine, University of Wisconsin

Medical School, Madison, WI, 53792, USA

SO Journal of Neurochemistry (2000), 74(1), 52-59 CODEN: JONRA9; ISSN: 0022-3042

PB Lippincott Williams & Wilkins

DT Journal

LA English

AB Using a cell-free translation system, we previously demonstrated that the

turnover and translation of amyloid precursor protein (APP) mRNA was regulated by a 29-nucleotide instability element, located 200 nucleotides downstream from the stop codon. Here we have examined the

regulatory role of this element in primary human capillary endothelial

cells under different nutritional conditions. Optimal proliferation

required a growth medium (endothelial cell growth medium) supplemented

with epidermal, basic fibroblast, insulin-like, and vascular endothelial

growth factors. In vitro transcribed mRNAs with the 5'-untranslated

region (UTR) and coding region of  $\beta$ -globin and the entire 3'-UTR of

APP 751 were transfected into cells cultured in endothelial cell growth medium. Wild-type globin-APP mRNA containing an intact APP 3'-UTR and mutant globin-APP mRNA containing a mutated

29-nucleotide element decayed with identical half-lives (t1/2 = 60 min).

Removal of all supplemental growth factors from the culture medium

significantly accelerated the decay of transfected wild-type mRNA (t1/2 =

10 min), but caused only a moderate decrease in the half-life of transfected mutant mRNA ( $t1/2 = 40 \, \text{min}$ ). We therefore conclude that the

29-nucleotide 3'-UTR element is an mRNA destabilizer whose function can be

inhibited by inclusion of the aforementioned mixture of growth factors in

the culture medium.

RE.CNT 47 THERE ARE 47 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 3 OF 3 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:187915 CAPLUS

DN 124:252087

OREF 124:46496h,46497a

TI Interactions of INS (CRS) elements and the splicing machinery regulate the

production of Rev-responsive mRNAs

AU Mikaelian, Ivan; Krieg, Marion; Gait, Michael J.; Karn, Jonathan

CS MRC Lab. Mol. Biol., Cambridge, CB2 2QH, UK

SO Journal of Molecular Biology (1996), 257(2), 246-64 CODEN: JMOBAK; ISSN: 0022-2836

PB Academic

DT Journal

LA English

AB The human immunodeficiency virus type 1 (HIV-1) Rev protein stimulates the

export to the cytoplasm of unspliced HIV-1 mRNAs carrying the Rev response

element (RRE). However, simple addition of the RRE to  $\beta\text{-globin}$  pre-mRNA

does not confer a Rev response on this heterologous transcript. In this

paper, the authors demonstrate that a strong Rev response is conferred on

 $\beta\text{-globin}$  pre-mRNA when an inhibitory (INS) elements is inserted into

the gene together with the RRE. In the presence of the INS element, Rev

was able to stimulate the export to the cytoplasm of unspliced mRNA 10 to

15-fold. INS elements from the HIV-1 pl7 gag and pol genes were equally

active in complementing Rev-dependent nuclear export of unspliced mRNA.

By contrast, mutated p17 gag INS element, known to be inactive in gag

mRNA instability assays, was unable to complement the Rev/RRE system and stimulate nuclear export. Similarly, AUUUA-instability elements from the granulocyte-macrophage colony stimulating factor mRNA

(GM-CSF) destabilized  $\beta\text{-globin}$  mRNA but could not substitute for the

 $\mbox{\rm HIV}$  INS elements. Complementation between the  $\mbox{\rm Rev/RRE}$  system and the INS

elements was only observed when splicing was efficient. When splicing of the

 $\beta$ -globin gene receptor is impaired by mutations in the 5' splicing of

the  $\beta\text{-globin}$  gene receptor is impaired by mutations in the 5' splice

donor, the 3' splice acceptor sequence, or the polypyrimidine tract, the

majority of the unspliced mRNA is exported from the nucleus in the absence

of Rev. In the presence of splice site mutations, Rev is able to act

independently of a functional INS element and increase the export of

unspliced mRNA three to fivefold. The authors propose that nuclear

factor(s) binding to INS elements sep. unspliced  $\beta\text{-globin}$  pre-mRNA

from the splicing apparatus Pre-mRNA in this "INS compartment" remains accessible to Rev. Thus, there is a synergy between the INS

elements and accessible to Rev. Thus, there is a synergy between the INS

elements and Rev which leads to enhanced nuclear export of unspliced mRNA.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	40.74	41.37
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE	TOTAL
	ENTRY	SESSION
CA SUBSCRIBER PRICE -2.40	-2.40	

FILE 'STNGUIDE' ENTERED AT 15:38:21 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 29, 2008 (20080829/UP).

=> FIL BIOSIS CAPLUS EMBASE COST IN U.S. DOLLARS

FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL SESSION

CA SUBSCRIBER PRICE

ENTRY 0.00

-2.40

FILE 'BIOSIS' ENTERED AT 15:41:06 ON 02 SEP 2008 Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:41:06 ON 02 SEP 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:41:06 ON 02 SEP 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> s 12 and bc1-2

L6 10 L2 AND BCL-2

=> dup rem 16

PROCESSING COMPLETED FOR L6

L7 6 DUP REM L6 (4 DUPLICATES REMOVED)

=> d bib abs 1-

YOU HAVE REQUESTED DATA FROM 6 ANSWERS - CONTINUE? Y/(N):y

L7 ANSWER 1 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 1

AN 2008:342473 BIOSIS

DN PREV200800342472

TI The nucleolin targeting aptamer AS1411 destabilizes bcl-2 messenger RNA in human breast cancer cells.

AU Soundararajan, Sridharan; Chen, Weiwei; Spicer, Eleanor K.; Courtenay-Luck, Nigel; Fernandes, Daniel J. [Reprint Author]

CS Med Univ S Carolina, Dept Biochem and Mol Biol, 176 Ashley Ave, Charleston, SC 29425 USA fernand@musc.edu

SO Cancer Research, (APR 1 2008) Vol. 68, No. 7, pp. 2358-2365. CODEN: CNREA8. ISSN: 0008-5472.

DT Article

LA English

ED Entered STN: 11 Jun 2008 Last Updated on STN: 11 Jun 2008

AB sought to determine whether nucleolin, a bcl-2 mRNA-binding protein, has a role in the regulation of bcl-2 mRNA stability in MCF-7 and MDA-MB-231 breast cancer cells. Furthermore, we examined the efficacy of the aptamer AS1411 in targeting

nucleolin and inducing bcl-2 mRNA

instability and cytotoxicity in these cells. AS1411 at 5 mu mol/L

inhibited the growth of MCF-7 and MDA-MB-231 cells, whereas 20 mu mol/L  $\,$ 

AS1411 had no effect on the growth rate or viability of normal MCF-10A

mammary epithelial cells. This selectivity of AS1411 was related to a

greater uptake of AS1411 into the cytoplasm of MCF-7 cells compared with

MCF-10A cells and to a 4-fold higher level of cytoplasmic nucleolin in

 $\mbox{MCF-7}$  cells. Stable siRNA knockdown of nucleolin in MCF-7 cells reduced

nucleolin and bcl-2 protein levels and decreased the

half-life of bcl-2 mRNA from 11 to 5 hours.

Similarly, AS1411 (10 mu mol/L) decreased the half-life of bcl-

2 mRNA in MCF-7 and MDA-MB-231 cells to 1.0 and 1.2 hours,

respectively. In contrast, AS1411 had no effect on the stability of

bcl-2 mRNA in normal MCF-10A cells. AS1411 also
 inhibited the binding of nucleolin to the instability element
AU-rich

element 1 of bcl-2 mRNA in a cell-free system and in MCF-7 cells. Together, the results suggest that AS1411 acts as a molecular decoy by competing with bcl-2 mRNA for

binding to cytoplasmic nucleolin in these breast cancer cell times. This

interferes with the stabilization of bcl-2 mRNA by nucleolin and may be one mechanism by which AS1411 induces tumor cell

death.

L7 ANSWER 2 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN  $\,$ 

AN 2006:182353 BIOSIS

DN PREV200600184465

TI Mode of action of rituximab in chronic lymphocytic leukaemia; Activation

of Tisllb, an inducer of mRNA instability, and induction of apoptosis.

AU Baou, Maria [Reprint Author]; Murphy, John; Jewell, Andrew P.

CS Kingston Univ, Sch Life Sci, Surrey, UK

SO Blood, (NOV 16 2005) Vol. 106, No. 11, Part 1, pp. 593A.

Meeting Info.: 47th Annual Meeting of the

American-Society-of-Hematology.

Atlanta, GA, USA. December 10 -13, 2005. Amer Soc Hematol. CODEN: BLOOAW. ISSN: 0006-4971.

DT Conference; (Meeting)

LA English

ED Entered STN: 15 Mar 2006

Last Updated on STN: 5 Jun 2008

AB Rituximab is a chimeric anti-CD20 monoclonal antibody that has been used

successfully in the treatment of Non Hodgkin's Lymphoma or patients with

Chronic Lymphocytic Leukaemia (CLL). The mechanisms of action of Rituximab are not fully understood although antibody dependent cell

mediated cytotoxicity and complement dependent cytoxicity have been shown

to be important. An alternative mechanism is the induction of apoptosis

through activation of pathways mediated through CD20. CD20 is involved in

many cellular processes including proliferation, activation, differentiation and apoptosis. We have found that treatment of CILL cells

with 20 mu g/ml Rituximab cross-linked will) a secondary antibody reduced

cell viability from 84 +/- 8% (in unstimulated cells) to 51.50 +/- 10%

after 48h of cultivation by the Annexin/PI method. Using inhibitors

specific for p38, JNK and ERK pathways, we found that inhibition of p38

inhibits the induction of apoptosis by crosslinked Rituximab. Rituximab

has been reported to inhibit this pathway andlead to down regulation of

bcl-2 expression in AIDS related lymphoma cells.

Ι

However the mechanism is unclear. One mechanism by which many genes

involved in apoptosis are regulated is through induction of mRNA instability through induction of Tis 11 family genes. The Tis I

family (Tis 11, Tis 11b/Berg36 and Tis 11d) bind to AU Rich elements

present in several mRNA (eg bcl-2, TNF) and cause their degradation. We found that Tis 11b/Berg36 is strongly induced by

crosslinked Rituximab. Tis I Id was weakly induced while Tis I I remained

unchanged after treatment. Furthermore we found that induction of Tis

11b/Berg36 by Rituximab is partly regulated through the p38 pathway since

inhibition of this pathway resulted partial or complete inhibition of Tis

11b/Berg36 induction. This suggests that Tis 11b/Berg36 may mediate the

induction of apoptosis by Rituximab through the degradation of proteins

involved in apoptosis that contain AU Rich elements, disrupting autocrine

cytokine feedback mechanisms and down regulating bc1-2

L7 ANSWER 3 OF 6 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 2

AN 2005:126151 BIOSIS

DN PREV200500121589

TI Retinoid-induced apoptosis in HL-60 cells is associated with nucleolin

down-regulation and destabilization of bcl-2 mRNA.

AU Otake, Yoko; Sengupta, Tapas K.; Bandyopadhyay, Sumita; Spicer, Eleanor

K.; Fernandes, Daniel J. [Reprint Author]

CS Dept Biochem and Mol Biol, Med Univ S Carolina, 173 Ashley Ave, POB 250509,

Charleston, SC, 29425, USA

fernand@musc.edu

SO Molecular Pharmacology, (January 2005) Vol. 67, No. 1, pp. 319-326. print.

ISSN: 0026-895X (ISSN print).

DT Article

LA English

ED Entered STN: 1 Apr 2005

Last Updated on STN: 1 Apr 2005

AB All-trans retinoic acid (ATRA) induces differentiation of promyelocytic

leukemia cells, but the mechanisms by which cellular differentiation leads

to apoptosis are not well understood. Studies were done to address the

question whether ATRA-induced apoptosis is a consequence of destabilization of bcl-2 mRNA and decreased cellular

levels of the anti-apoptotic protein, bcl-2. ATRA

induced differentiation of HL-60 cells along the granulocytic pathway

within 48 h. The half-lives of bcl-2 mRNA in HL-60

cells incubated with ATRA for 48 or 72 h were reduced to 39 and 7% of the

corresponding untreated control values, respectively. Cellular differentiation was accompanied by down-regulation of the cytoplasmic

levels of nucleolin, a bcl-2 mRNA-stabilizing protein.

Binding of a bcl-2 mRNA instability

element (AU- rich element-1) to nucleolin in S100 extracts from ATRA-treated cells was decreased to 15% of control within 72 h. The decay

of 5' capped, polyadenylated bcl-2 mRNA transcripts containing ARE-1 was more rapid in S100 extracts from ATRA-treated cells

compared with untreated cells. However, when recombinant nucleolin was

added to extracts of ATRA-treated cells, the rate of bcl-2 mRNA decay was similar to the rate in extracts of untreated cells. These results provide evidence that ATRA-induced apoptosis is a

consequence of cellular differentiation, which leads to nucleolin down-regulation and bcl-2 mRNA instability.

L7 . ANSWER 4 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2004:999715 CAPLUS

DN 141:406751

TI Assay and expression systems comprising reporter gene and instability

sequence DNA for identifying compounds which affect stability of mRNA

IN Kastelic, Tania; Cheneval, Dominique

PA Novation Pharmaceuticals Inc., Can.

SO U.S. Pat. Appl. Publ., 49 pp., Cont.-in-part of U.S. Ser. No. 869,159.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 2

PATENT NO.	KIND DATE	APPLICATION NO.
DATE		
	A1 20041118	US 2004-814634
20040401 WO 2000039314	A1 20000706	WO 1999-CA1235
19991223	AI 20000700	WO 1999-CA1233
	AT, AU, AZ, BA,	BB, BG, BR, BY, CA, CH, CN,
CR, CU,	חא פי פי פיד	GB, GD, GE, GH, GM, HR, HU,
ID, IL,	DM, EE, ES, FI,	GB, GD, GE, GH, GM, HK, HO,
IN, IS, JP,	KE, KG, KP, KR,	KZ, LC, LK, LR, LS, LT, LU,
LV, MA,	MN MW MX NO	NZ, PL, PT, RO, RU, SD, SE,
SG, SI,	MA, MA, MA, MO,	N2, 11, 11, 10, 10, 55, 51,
	TM, TR, TT, TZ,	UA, UG, US, UZ, VN, YU, ZA,
ZW RW: GH. GM. KE.	LS. MW. SD. SL.	SZ, TZ, UG, ZW, AT, BE, CH,
CY, DE,	25,, 55, 62,	22, 12, 33, 2, 111, 22, 611,
	FR, GB, GR, IE,	IT, LU, MC, NL, PT, SE, BF,
BJ, CF, CG, CT, CM,	GA. GN. GW. MI.	MR, NE, SN, TD, TG
		AU 2005-229165
20050401	24 00055050	G3 0005 0503505
CA 2603585 20050401	A1 20051013	CA 2005-2603585
20050102		

```
WO 2005095615
                       A1
                                20051013 WO 2005-CA491
20050401
             AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ,
CA, CH,
             CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI,
GB, GD,
             GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR,
KZ, LC,
             LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NA, NI,
             NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK,
SL, SM,
             SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,
ZA, ZM, ZW
         RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM,
ZW, AM,
             AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ,
DE, DK,
             EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL,
PL, PT,
             RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ,
GW, ML,
             MR, NE, SN, TD, TG
                                20070418 EP 2005-730094
     EP 1774000
                          A1
20050401
         R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR,
HU, IE,
             IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR
                          Т
                                20071101
                                            JP 2007-505349
     JP 2007530058
20050401
     US 20070190532
                          A1
                                20070816
                                            US 2007-594851
20070504
PRAI GB 1998-28709
                          Α
                                19981224
     WO 1999-CA1235
                                19991223
                          W
     US 2001-869159
                          A2
                                20010815
     US 2004-814634
                          Α
                                20040401
     WO 2005-CA491
                          W
                                20050401
     The present invention relates to an assay for the identification
AB
of biol.
     active compds., in particular to a reporter gene assay for the
```

active compds., in particular to a reporter gene assay for the identification of compds., which have an effect on mRNA stability. More

particularly, the present invention relates to a reporter gene expression

system and cell lines comprising said expression system. The invention

further relates to compds. which destabilize mRNA. Radicicol and radicicol analog A showed a clear effect on mRNA stability. Human APP,

Bcl-2.alpha., c-myc, TNF $\alpha$ , IL-1 $\beta$ , VEGF

instability sequence were constructed. Instability sequence DNA is from

The gene encoding a cytokine, a gene encoding a chemokine, a gene encoding

a nuclear transcription factor, a gene encoding an oxygenase, a proto-oncogene, an immediate early gene, a cell cycle controlling gene,

and a gene involved in apoptosis.

L7 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:208720 CAPLUS

DN 143:41672

TI Mitochondrial DNA microsatellite instability and expression of Bcl

-2 and Bax mRNA in gastric cancer and its precancerous lesions AU Fang, Dianchun; Ling, Xianlong; Luo, Yuanhui

CS Research and Treatment Center for Digestive Diseases of PLA, Southwest

Hospital, Third Military Medical University, Chongqing, 400038, Peop. Rep.

China

SO Jiefangjun Yixue Zazhi (2003), 28(11), 982-984 CODEN: CFCHBN; ISSN: 0577-7402

PB Jenminjun Chubanshe

DT Journal

LA Chinese

AB The relation between mitochondrial DNA microsatellite instability (mtMSI)

and the expression of Bcl-2 and Bax mRNA in gastric cancer and precancerous lesions was studied. MtMSI and expression of

Bcl-2 and Bax mRNA were detected with PCR-SSCP and RT-PCR, resp. Expression of Bcl-2 mRNA in intestinal metaplasia (IM, 53.3%) and dysplasia (Dys, 70%) were significantly higher

than that in normal control tissue (10%), whereas no significant differences were found among chronic gastritis (CAG, 50%), gastric cancer

(GC, 30%) and normal controls. Expression of Bcl-2 mRNA in Dys was higher than that in GC. Expression of Bax mRNA was

significantly increased in Dys (60%), but not in CAG (50%), IM (46.7%) and

GC (33.3), compared with normal control (10%). Expression of Bcl -2 and Bax mRNA in Helicobacter pylori infected gastric mucosa was significantly higher than that in non-H. pylori infected gastric

mucosa, but expression of Bcl-2 and Bax mRNA were not consistent with H. pylori CagA status. MtMSI levels were 0, 10.0, 13.3,

20.0, and 36.7% in controls, CAG, IM, Dys, and GC, resp. No significant

difference was found between the expression of Bcl-2 and Bax mRNA in mtMSI(+) and that in mtMSI(-) tissues. MtMSI may play an

important role in some gastric cancers, and increased mtMSI is independent of abnormal expression of Bcl-2 and Bax mRNA.

L7 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:240751 CAPLUS

DN 136:279323

TI Preparation of lactone-containing benzoate esters and their use as

pharmaceutical use

IN Kastelic, Tania; Cheneval, Dominique; Leutwiler, Albert

PA Novation Pharmaceuticals Inc., Can.

SO PCT Int. Appl., 57 pp.

CODEN: PIXXD2

JP 2004509167

20010921

DT Patent

LA English

FAN.CNT 1 PATENT NO.	KIND DATE	APPLICATION NO.				
DATE						
PI WO 2002024674 20010921	A1 20020328	WO 2001-CA1331				
W: AE, AG, AL,	AM, AT, AU, AZ,	BA, BB, BG, BR, BY, BZ, C	CΑ,			
CH, CN,						
	CZ, DE, DK, DM,	DZ, EC, EE, ES, FI, GB, C	ЗD,			
GE, GH,	TD II IN IG	ד עם עם עם עם עם די				
	1D, 1L, 1N, 1S,	JP, KE, KG, KP, KR, KZ, I	JC,			
LK, LR,	T.V MA MD MG	MK, MN, MW, MX, MZ, NO, N	VZ.			
PH, PL,	24, 121, 115, 116,	,,,,,,	,			
	SD, SE, SG, SI,	SK, SL, TJ, TM, TR, TT, T	ΓZ,			
UA, UG,						
·	YU, ZA, ZW					
	LS, MW, MZ, SD,	SL, SZ, TZ, UG, ZW, AT, F	3E,			
CH, CY,		TO TO III NO NI DO (	a ==			
·	FI, FR, GB, GR,	IE, IT, LU, MC, NL, PT, S	ΣE,			
TR, BF,	CT CM GA GN	GQ, GW, ML, MR, NE, SN, T	מיז			
TG	017 017 017	52, GM, 112, 1110, 112, 510, 1	,			
CA 2420185	A1 20020328	CA 2001-2420185				
20010921						
AU 2001093555	A 20020402	AU 2001-93555				
20010921						
EP 1318991	A1 20030618	EP 2001-973891				
20010921 PD 1210001						
EP 1318991	B1 20060816	GB, GR, IT, LI, LU, NL, S	C F			
MC, PT,	DE, DR, EB, FR,	GD, GR, II, DI, DO, NII, S	æ,			
110, 11,						

IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

20040325 JP 2002-529084

Т

AT 336487	T	20060915	AT 2001-973891
20010921			
ES 2276829	Т3	20070701	ES 2001-973891
20010921			
US 20050049202	A1	20050303	US 2003-381294
20030321			
PRAI CA 2000-2320664	A	20000921	
WO 2001-CA1331	W	20010921	
OS MARPAT 136:279323			
GI			

$$R^4$$
 $R^5$ 
 $Y$ 
 $(CH_2)_n$ 
 $R^6$ 
 $R^7$ 
 $R^7$ 
 $R^7$ 
 $R^8$ 

AB The title compds. [I; R1-R5 = H, OH, halogen, (C1-4) alkyl, (C1-4)

I

alkenyl, (C1-4) alkoxy, (C1-4) alkyl-CO2; Y = O, NR; R = H, (C1-4) alkyl;

n = 0-8; R6 = 5-8-membered (un) substituted (un) saturated lactone or lactam

ring; R7 = H, (C1-4) alkyl, (C1-4) alkenyl, (C1-4) alkoxy, Ph, (C1-4)

alkyl-CO2], which are useful for the treatment or prevention of disorders

with an etiol. associated with or comprising excessive cytokine release and

are also used in the treatment of cancer, inflammatory disorders and

disorders associated with an increased stability of  $\ensuremath{\mathsf{mRNA}}$  which has an

mRNA instability sequence; I-containing pharmaceutical formulation are presented. Compound II, prepared via esterification of the

corresponding chiral hydroxymethyl-substituted lactone with

2-methoxy-6-methylbenzoic acid, demonstrated activity against THP-1 cell lines. RE.CNT 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT => s bcl2 and AU 43 BCL2 AND AU L8 => dup rem 18 PROCESSING COMPLETED FOR L8 1.9 36 DUP REM L8 (7 DUPLICATES REMOVED) => s 19 and PY<=1998 5 L9 AND PY<=1998 L10 => d bib abs 1-YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y ANSWER 1 OF 5 BIOSIS COPYRIGHT (c) 2008 The Thomson L10 Corporation on STN 1997:199800 BIOSIS AN PREV199799499003 DNPeripheral blood stem cell CD34+ autologous transplant in TI relapsed follicular lymphoma. Marin, G. H.; Dal Cortivo, L.; Cayuela, J. M.; Marolleau, J. P.; ΑU Pautier, P.; Cojean-Zelek, I.; Brice, P.; Makke, J.; Benbunan, M.; Gisselbrecht, C. [Reprint author] Serv. Reanimation Hematol. Adulte, Hopital Saint-Louis, 1 avenue CS Claude Vellefaux, F-75475 Paris cedex 10, France Hematology and Cell Therapy, (1997) Vol. 39, No. 1, pp. 33-40. SO ISSN: 1269-3286. Article DTEnglish LA Entered STN: 12 May 1997 ED Last Updated on STN: 12 May 1997 To evaluate CD34+ selection of peripheral blood stem cells AB (PBSC) as a graft for autologous transplantation. Eight relapsing follicular lymphoma (FL) patients were submitted to CD34+ autologous stem cell transplantation (ASCT). All patients received at least two front line conventional therapies; mean time to treatment failure (TTF) was 4.5 months. Patients

had disseminated stage III-IV disease after a median number of

2.1

relapses. Chemotherapy and G-CSF were used as mobilization for leukapheresis. CEPRATE SC concentrator (Cell Pro, Inc, Bothell, WA) was

used to select CD34+ cells from leukapheresis products. With a mean of

1.8 leukaphereses per patient, 8.1 times 10-8 mononuclear cells (MNCs)/kg

were collected. After the selection process, the median number of MNCs

was 9.4 times 10-6/kg; 4.3 times 10-6/kg CD34+ cells and 17 times 10-4/kg

CFU-GM, with a purity of 83.7% and a viability of 89.2%. Mbr bcl2

/IgH PCR analysis of 5 grafts showed that initial buffy-coat, and CD34-

fractions were negative in 3 cases and positive in 2 cases (from whom

selected CD34+ fraction remained positive in 1 case). After a conditioning regimen including total body irradiation, cyclophosphamide

and etoposide, CD34+ selected cells were reinfused. AU patients but one had successful engraftment, median time to WBC gt 1 times 10-9/1

was 12 days and platelets gt 50 times 10-9/l 17 days. No severe infectious complications were seen. After transplant, with a minimum

follow up of 2 years, 5 patients are still in complete remission (CR).

Three patients have relapsed after 1 year of transplant with a mean TTF of

15.6 months. We conclude that PBSC CD34+ selection for ASCT was a safe

technique, capable of reconstituting hemopoiesis without severe complications for high risk FL patients included in this study.

effects of tumor cell purging need to be evaluated in a larger series.

L10 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

AN 1994:485444 BIOSIS

DN PREV199497498444

TI Differential induction of apoptosis in human breast tumor cells by okadaic

acid and related inhibitors of protein phosphatases 1 and 2A.

AU Kiguchi, Kaoru; Glesne, David; Chubb, Cynthia H.; Fujiki, Hirota; Huberman, Eliezer [Reprint author]

CS Argonne National Lab., 9700 S. Cass Ave., Argonne, IL 60439, USA

SO Cell Growth and Differentiation, (1994) Vol. 5, No. 9, pp. 995-1004.

ISSN: 1044-9523.

DT Article

The

LA English

ED Entered STN: 9 Nov 1994

Last Updated on STN: 16 Dec 1994

AB To investigate a possible relationship between apoptosis induction and

protein phosphorylation in human breast carcinoma cells, we treated three

such cell types, MB231, MCF-7, and AU-565, with okadaic acid (OA), an inhibitor of protein phosphatases 1 and 2A, or phorbol 12

myristate 1 3-acetate, an activator of protein kinase C. We then examined

these cells for the appearance of apoptosis markers. While OA caused

multiplication arrest and cytotoxicity in all three cell lines, apoptosis

was induced in MB-231 and MCF-7 cells but not in AU565 cells. A similar  $\,$ 

cell-specific apoptosis induction was also observed after treatment with

dinophysistoxin-1 (an active OA analogue) and with calyculin A (a structurally unrelated protein phosphatase inhibitor) but not with

analogues that either are inactive or penetrate epithelial cells poorly.

Phorbol 12-myristate 13-acetate also inhibited cell multiplication but was

without effect in inducing apoptosis in these cells. Levels of the

apoptosis-inhibitory protein BCL2 were examined in these cells, but they did not correlate with this differential susceptibility. We

additionally treated the three cell types with 1-beta-Darabinofuranosylcytosine and genistein to determine whether the

-565 cell line would also be resistant to apoptosis induction by other

chemical stimuli. Both of these agents led to the induction of apoptosis

in all three cell lines. These results indicate that the AU-565 cells are specifically resistant to apoptosis induction by inhibitors of

protein phosphatases 1 and 2A. This cell-specific resistance may thus

allow one to identify cellular mediators of apoptosis by comparing protein

phosphorylation patterns in these cells before and after treatment with OA

or related inhibitors.

L10 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN AN 1996:463418 CAPLUS

DN 125:139307

OREF 125:26029a,26032a

TI A bcl-2/IgH antisense transcript deregulates bcl-2 gene expression in

human follicular lymphoma t(14:18) cell lines

AU Capaccioli, S.; Quattrone, A.; Schiavone, N.; Calastretti, A.; Copreni,

E.; Bevilacqua, A.; Canti, G.; Gong, L.; Morelli, S.; Nicolin, A.

CS Inst. Gen. Pathol., Univ. Florence, Florence, 50134, Italy

SO Oncogene (1996), 13(1), 105-115

CODEN: ONCNES; ISSN: 0950-9232

PB Stockton

DT Journal

LA English

AB The 14;18 chromosome translocation, characteristic of most human follicular B-cell lymphomas, juxtaposes the bcl-2 gene with the IgH locus,

creating a bcl-2/IgH hybrid gene. By mechanisms that are still under

investigation, this event increases the cellular levels of the bcl-2 mRNA

and thereby induces an overprodn. of the antiapoptotic BCL-2 protein which

is likely responsible for neoplastic transformation. In an effort to

identify potential upregulators of bcl-2 activity in t(14;18) cells, a

bcl-2 antisense transcript was found by strand-specific RT-PCR that is

present in the t(14;18) DOHH2 and SU-DHL-4 but not in the t(14;18)-neg.

Raji and Jurkat lymphoid cell lines, and thus appears to be dependent on

the bcl-2/IgH fusion. This antisense transcript is a hybrid bcl-2/IgH

RNA, that originates in the IgH locus, encompasses the t(14;18) fusion

site and spans at least the complete 3' UTR region of the bcl-2 mRNA. To  $\dot{\mbox{}}$ 

achieve some insight into its biol. function, the t(14;18) DOHH2 cell line

was treated with oligonucleotides (ODNs) by specifically targeting the

bcl-2/IgH antisense strand. These ODNs lowered bcl-2 gene expression and

inhibited neoplastic cell growth by inducing apoptosis. Thus, the

bcl-2/IgH antisense transcript may contribute, by an unknown mechanism, to

upregulation of bcl-2 gene expression in t(14;18) cells. The possibility

has been considered that the hybrid antisense transcript mask AU

-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in  $\,$ 

other genes as mRNA destabilizing elements.

L10 ANSWER 4 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:183430 CAPLUS

DN 124:285072

OREF 124:52719a,52722a

TI BCL-2 expression or antioxidants prevent hyperglycemia-induced formation

of intracellular advanced glycation endproducts in bovine endothelial

cells

AU Giardino, Ida; Edelstein, Diane; Brownlee, Michael

CS Department of Medicine, Albert Einstein College of Medicine, New York, NY,

10461, USA

SO Journal of Clinical Investigation (1996), 97(6), 1422-8 CODEN: JCINAO; ISSN: 0021-9738

PB Rockefeller University Press

DT Journal

LA English

AB Hyperglycemia rapidly induces an increase in intracellular advanced

glycation end products (AGEs) in bovine endothelial cells, causing an

alteration in bFGF activity. Because sugar or sugar-adduct autoxidn. is

critical for AGE formation in vitro, the role of reactive oxygen species

(ROS) in intracellular. AGE formation was evaluated by using bovine aortic

endothelial cells. Glucose (30 mM) increased intracellular ROS formation

by 250% and lipid peroxidn. by 330%, while not affecting ROS in the media.

In cells depleted of glutathione, intracellular AGE accumulation increased

linearly with ROS generation as measured by immunoblotting and the

fluorescent probe DCFH (AGE 0.258-3.531 AU\* mm/5 + 104 cells, DCF 57-149 mean AU, r = 0.998, P < 0.002). Deferoxamine,  $\alpha\text{-tocopherol}$ , and dimethylsulfoxide each inhibited

hyperglycemia-induced formation of both ROS and AGE. To differentiate an

effect of ROS generation on AGE formation from an effect of more distal

oxidative processes,  ${\tt GM7373}$  endothelial cell lines were generated that

stably expressed the peroxidn.-suppressing proto-oncogene bcl-2.

had no effect on hyperglycemia-induced intracellular ROS formation. In

contrast, bcl-2 expression decreased both lipid peroxidn. (100% at 3 h and

29% at 168 h) and AGE formation (55% at 168 h). These data show that a

ROS-dependent process plays a central role in the generation of intracellular AGEs, and that inhibition of oxidant pathways prevents

intracellular AGE formation.

L10 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1987:33148 CAPLUS

DN 106:33148

OREF 106:5567a,5570a

TI A folded and a planar 1,3-diboretane

AU Hornbach, Pia; Hildenbrand, Manfred; Pritzkow, Hans; Siebert, Walter

CS Anorg.-Chem. Inst., Univ. Heidelberg, Heidelberg, D-6900, Fed.

Rep. Ger.

SO Angewandte Chemie (1986), 98(12), 1121-3

CODEN: ANCEAD; ISSN: 0044-8249

DT Journal

LA German

OS CASREACT 106:33148

GI

N(CHMe<sub>2</sub>)<sub>2</sub>

AB Treatment of B2Cl4 with Me3SiC.tplbond.CSiMe3 gave (Me3Si)2C:C(BCl2)2 which was treated with (Me2CH)2NH to give

IV

(Me3Si)2C:C[BClN(CHMe2)2]2. Treatment of the latter compound with NaK8 gave

the diborate I which gave a stable dianion (II) by treatment with more

NaK8. Hydrogenation of I gave the diboretane III which was also obtained

by treating II with CHCl3 or HN(SiNe3)2. Treatment of II with Ph3PAuCl

gave the Au derivative IV.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 54.54 96.21 FULL ESTIMATED COST

TOTAL DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE E FILE TOTAL ENTRY SESSION

-4.80 CA SUBSCRIBER PRICE

-7.20

FILE 'STNGUIDE' ENTERED AT 15:49:29 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION. LAST RELOADED: Aug 29, 2008 (20080829/UP).

=> FIL BIOSIS CAPLUS EMBASE

COST IN U.S. DOLLARS

SINCE FILE TOTAL ENTRY SESSION 0.06 96.27 FULL ESTIMATED COST

SINCE FILE DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) TOTAL

ENTRY SESSION

0.00 CA SUBSCRIBER PRICE

-7.20

FILE 'BIOSIS' ENTERED AT 15:49:55 ON 02 SEP 2008 Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:49:55 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT. PLEASE SEE "HELP USAGETERMS" FOR DETAILS. COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:49:55 ON 02 SEP 2008 Copyright (c) 2008 Elsevier B.V. All rights reserved.

=> d his

Ll

(FILE 'HOME' ENTERED AT 15:24:37 ON 02 SEP 2008)

FILE 'BIOSIS, CAPLUS, EMBASE' ENTERED AT 15:26:25 ON 02 SEP 2008

19 S MRNA (3A) INSTABIL? SEQUENCE

964 S MRNA (3A) INSTABIL? L2

OS L1 AND APP L3

3 S L2 AND APP L4

3 DUP REM L4 (0 DUPLICATES REMOVED) L5

FILE 'STNGUIDE' ENTERED AT 15:38:21 ON 02 SEP 2008

FILE 'BIOSIS, CAPLUS, EMBASE' ENTERED AT 15:41:06 ON 02 SEP 2008

L6 10 S L2 AND BCL-2

L7 6 DUP REM L6 (4 DUPLICATES REMOVED)

L8 43 S BCL2 AND AU

L9 36 DUP REM L8 (7 DUPLICATES REMOVED)

L10 5 S L9 AND PY<=1998

FILE 'STNGUIDE' ENTERED AT 15:49:29 ON 02 SEP 2008

FILE 'BIOSIS, CAPLUS, EMBASE' ENTERED AT 15:49:55 ON 02 SEP 2008

=> s BCL 2 and (ARE or AU)

L11 28853 BCL 2 AND (ARE OR AU)

=> FIL STNGUIDE

COST IN U.S. DOLLARS SINCE FILE TOTAL

ENTRY SESSION

FULL ESTIMATED COST 11.53 107.80

"DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

ENTRY SESSION

ENTRY

SESSION

CA SUBSCRIBER PRICE 0.00

-7.20

FILE 'STNGUIDE' ENTERED AT 15:52:15 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.

LAST RELOADED: Aug 29, 2008 (20080829/UP).

=> FIL BIOSIS CAPLUS EMBASE

COST IN U.S. DOLLARS SINCE FILE TOTAL

FULL ESTIMATED COST 0.36 108.16

.

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL

CA SUBSCRIBER PRICE 0.00

-7.20

FILE 'BIOSIS' ENTERED AT 15:56:07 ON 02 SEP 2008

Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:56:07 ON 02 SEP 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 15:56:07 ON 02 SEP 2008

```
Copyright (c) 2008 Elsevier B.V. All rights reserved.
=> s AU (3a) rich
L12
          3839 AU (3A) RICH
=> s 112 and BCL 2
L13
            57 L12 AND BCL 2
=> s 113 and py<=1998
L14
             3 L13 AND PY<=1998
=> dup rem 114
PROCESSING COMPLETED FOR L14
L15
              1 DUP REM L14 (2 DUPLICATES REMOVED)
=> d bib abs
    ANSWER 1 OF 1 BIOSIS COPYRIGHT (c) 2008 The Thomson
L15
Corporation on STN
    DUPLICATE 1
AN
     1996:414837 BIOSIS
DN
    PREV199699137193
    A bcl-2/IgH antisense transcript deregulates
TI
    bcl-2 gene expression in human follicular lymphoma
     t(14;18) cell lines.
ΑU
     Capaccioli, S.; Quattrone, A.; Schiavone, N.; Calastretti, A.;
Copreni,
     E.; Bevilacqua, A.; Canti, G.; Gong, L.; Morelli, S.; Nicolin,
A. [Reprint
     author]
CS
    Dep. Pharmacol., Sch. Med., Via Vanvitelli 32, 20129 Milan, Italy
SO
     Oncogene, (1996) Vol. 13, No. 1, pp. 105-115.
     CODEN: ONCNES. ISSN: 0950-9232.
    Article
DT
    English
LA
ED
    Entered STN: 10 Sep 1996
     Last Updated on STN: 10 Sep 1996
    The 14;18 chromosome translocation, characteristic of most human
AB
     follicular B-cell lymphomas, juxtaposes the bcl-2 gene
     with the IgH locus, creating a bcl-2/IgH hybrid gene.
     By mechanisms that are still under investigation, this event
increases the
     cellular levels of the bcl-2 mRNA and thereby induces
     an overproduction of the antiapoptotic BCL-2 protein
     which is likely responsible for neoplastic transformation.
     to identify potential upregulators of bcl-2 activity
     in t(14;18) cells, we found, by strand-specific RT-PCR, a hcl-2
antisense
     transcript that is present in the t(14;18) DOHH2 and SU-DHL-4
but not in
     the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and
```

thus

appears to be dependent on the bcl-2/IgH fusion. This antisense transcript is a hybrid bcl-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and

spans at least the complete 3' UTR region of the bcl-2 mRNA. To achieve some insight into its biological function, we treated

the t(14;18) DOHH2 cell line with oligonucleotides (ODNs) by specifically

targeting the bcl-2/IgH antisense strand. These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis. We would like to propose the hypothesis that the bcl-2/IgH antisense transcript may contribute, by an unknown mechanism, to upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.

=> FIL STNGUIDE

COST IN U.S. DOLLARS

ENTRY
SESSION
FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE
TOTAL
ENTRY
SESSION
ENTRY
SESSION

CA SUBSCRIBER PRICE 0.00

-7.20

FILE 'STNGUIDE' ENTERED AT 15:58:18 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

FILE CONTAINS CURRENT INFORMATION.
LAST RELOADED: Aug 29, 2008 (20080829/UP).

=> FIL BIOSIS CAPLUS EMBASE

COST IN U.S. DOLLARS SINCE FILE TOTAL ENTRY SESSION FULL ESTIMATED COST 0.06 125.17

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL ENTRY SESSION

CA SUBSCRIBER PRICE 0.00

-7.20

FILE 'BIOSIS' ENTERED AT 15:58:39 ON 02 SEP 2008 Copyright (c) 2008 The Thomson Corporation

FILE 'CAPLUS' ENTERED AT 15:58:39 ON 02 SEP 2008 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

```
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
FILE 'EMBASE' ENTERED AT 15:58:39 ON 02 SEP 2008
Copyright (c) 2008 Elsevier B.V. All rights reserved.
=> s mRNA (3a) stabil?
        18718 MRNA (3A) STABIL?
L16
=> s 116 and bcl 2
L17
          120 L16 AND BCL 2
=> s 117 and pY <= 1998
            10 L17 AND PY<=1998
L18
=> dup rem 118
PROCESSING COMPLETED FOR L18
              5 DUP REM L18 (5 DUPLICATES REMOVED)
=> d bib abs 1-
YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N): Y
     ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN
L19
     1998:672675 CAPLUS
\mathbf{A}\mathbf{N}
     129:271496
DN
OREF 129:55245a,55248a
    Viral vectors for identification of RNA regulatory sequences and
TI
     interacting molecules
     Blau, Helen M.; Spicher, Albert; Guicherit, Oivin
IN
     The Board of Trustees of the Leland Stanford Junior University,
PA
USA
     PCT Int. Appl., 64 pp.
SO
     CODEN: PIXXD2
     Patent
DT
     English
LΑ
FAN.CNT 1
                   KIND DATE APPLICATION NO.
     PATENT NO.
DATE
                    A1 19981001 WO 1998-US6093
PI WO 9842854
19980327 <--
         W: CA, JP
         RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC,
NL, PT, SE
PRAI US 1997-42543P
                         P
                                19970327
    Methods and compns. for the identification, characterization and
isolation
     of regulatory RNA sequences are provided. Regulatory RNA
sequences
     mediate post-transcriptional regulation in response to various
```

environmental conditions and can be used to alter the level of

expression

of endogenous genes or to identify factors which interact with regulatory

RNA sequences. The invention addnl. provides improved vector systems for

rapid screening, anal., and tightly-regulated expression of regulatory RNA

sequences. The regulatory properties of highly conserved regions (HCRs)

within 3'-UTRs that have retained greater than 70% homol. within stretches

of 100 nucleotides over 30 million years were examined A retroviral vector

system was used with a selectable marker that allowed rapid delivery of

3'-UTR-reporter constructs to populations of thousands of cells within one

to two weeks, avoiding problems associated with clonal anal. and long-term

selection. Addnl., this vector is modular, thereby permitting direct

comparison of different HCRs on gene expression, independent of 5'-UTRs,

promoters, protein coding regions and polyadenylation signals. Ten HCRs

(from c-fos, c-myc, transferrin receptor, bcl2, EF1 $\alpha$ , vimentin, ornithine decarboxylase, fibronectin, HuD and Ran genes) were examined Nine

of these HCRs (i.e., all except the Ran HCR) were found to decrease

mRNA stability to different extents. Two HCRs (the c-fos and vimentin HCRs) altered mRNA translation under steady-state

conditions. Four HCRs (the HuD, Ran, fibronectin and ornithine decarboxylase HCRs) mediated responses to changes in mitogen level by

increasing reporter protein levels 2-fold while 2 HCRs exhibited a 6-fold

difference in their response to another environmental stress, hypoxia.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 2 OF 5 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 1

AN 1997:160160 BIOSIS

DN PREV199799459363

TI Increased gadd153 messenger RNA level is associated with apoptosis in

human leukemic cells treated with etoposide.

AU Eymin, Beatrice; Dubrez, Laurence; Allouche, Michele; Solary, Eric

[Reprint author]

CS Lab. Oncohematol. Pharmacol., CJF INSERM 94-08, UFR

Med./Pharmacy, 7

boulevard Jeanne d'Arc, 21033 Dijon, France

SO Cancer Research, (1997) Vol. 57, No. 4, pp. 686-695. CODEN: CNREA8. ISSN: 0008-5472.

DT Article

LA English

not

ED Entered STN: 15 Apr 1997

Last Updated on STN: 15 Apr 1997

AB Treatment of leukemic cells with topoisomerase inhibitors can lead to

growth arrest and subsequent apoptotic cell death. The relationships

between cell cycle regulation and apoptosis triggering remain poorly

understood. The gadd153 gene encodes the nuclear protein CHOP 10 that

acts as a negative modulator of CCAAT/enhancer binding protein transcriptional factors and inhibits cell cycle progression. We have

investigated the relationships between gadd153 gene expression and  $% \left( 1\right) =\left( 1\right) +\left( 1\right)$ 

apoptosis induction in four human leukemic cell lines with different

sensitivities to apoptosis induced by etoposide (VP-16), a topoisomerase

11 inhibitor. The gadd153 gene was constitutively expressed in the four

studied cell lines. In U937 and HL-60 cells that were very sensitive to

apoptosis induction by the drug, VP-16 induced a time- and dosedependent

increase of gadd153 gene mRNA expression. Using agarose gel electrophoresis and a quantitative filter elution assay, apoptotic DNA

fragmentation was observed to begin when gadd153 gene expression increased. Equitoxic doses of VP-16 (as defined using a 96-h 3-4,5-dimethylthiazol-2,5-diphenyltetrazolium bromide assay) did

increase the gadd153 mRNA level in K562 and KCL22 cell lines that were  $\,$ 

more resistant to apoptosis induction by the drug. Nuclear run-on and

mRNA stability experiments demonstrated that VP-16 treatment increased gadd153 gene transcription in the sensitive U937

cells. Cycloheximide did not prevent gadd153 expression increase. Both

gadd153 mRNA level increase and internucleosomal DNA fragmentation were  $% \left( 1\right) =\left( 1\right) +\left( 1\right) +\left($ 

inhibited by N-tosyl-L-phenylalanine chloromethylketone, a serine

threonine protease inhibitor, N-acetyl-leucyl-leucyl-norleucinal, an inhibitor of calpain, N-acetylcysteine, an inhibitor of oxidative metabolism, and overexpression of Bcl-2. Z-VAD and Z-DEVD peptides that inhibit interleukin 1-beta-converting enzyme-like proteases suppressed DNA fragmentation without preventing qadd153 mRNA increase in VP-16-treated U937 cells. These results indicate that qadd153 gene expression increase occurs downstream of events sensitive to N-tosyl-L-phenylalanine chloromethylketone, calpain inhibitor I, and Bcl-2 and upstream of interleukin 1-beta-converting enzyme-related proteases activation in leukemic cells in which treatment with VP-16 induces rapid apoptosis. L19 ANSWER 3 OF 5 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights reserved on STN AN 1997289087 **EMBASE** Dexamethasone suppresses apoptosis in a human gastric cancer TIcell line through modulation of bcl-x gene expression. Chang, Tsu-Chung (correspondence); Chu, Jing-Tsai; Chu, Li-Ling ΑU Department of Biochemistry, Natl. Def. Med. Ctr., P.O. B., CS Taipei, Taiwan, Province of China. ΑU Hung, Mei-Whey; Tsai, Lai-Chen Department of Medical Research, Veterans General Hospital, CS Taipei, Taiwan, Province of China. ΑU Jiang, Shu-Yang Grad. Institute of Medical Sciences, National Defense Medical CS Center, Taipei, Taiwan, Province of China. Chang, Tsu-Chung (correspondence) ΑU Department of Biochemistry, National Defence Medical Center, PO CS Box 90048-501, Taipei, Taiwan, Province of China. FEBS Letters, (22 Sep 1997) Vol. 415, No. 1, pp. 11-15. SO Refs: 26 ISSN: 0014-5793 CODEN: FEBLAL S 0014-5793(97)01083-1 PUI CY Netherlands Journal; Article DT FS 016 Cancer Clinical and Experimental Biochemistry 029 Drug Literature Index 037 English LΑ English

SL

ED Entered STN: 9 Oct 1997

Last Updated on STN: 9 Oct 1997

AB Treatment of human gastric cancer TMK-1 cells with transcription and

translation inhibitors rapidly triggered cell apoptosis. Along with cell

apoptosis, the Bcl-x(S) level was markedly upregulated suggesting a

crucial role of this protein in promoting tile apoptotic process. In the

presence of dexamethasone, however, cell apoptosis was greatly attenuated

as demonstrated by DNA histogram shift and DNA fragmentation. Studies

using the glucocorticoid receptor antagonist RU486 indicated that attenuation of apoptosis was mediated through glucocorticoid receptors.

Dexamethasone not only suppressed the apoptosis-associated upregulation of

Bcl-x(S) but also enhanced the basal level of Bcl-x(L) in the cells. In

addition, bcl-x mRNA stability was significantly extended in the presence of dexamethasone, These results indicate that

dexamethasone exerted a protective effect and delayed apoptosis of TMK-1

cells by modulating bcl-x gene expression.

L19 ANSWER 4 OF 5 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 2

AN 1997:42737 BIOSIS

DN PREV199799334725

TI Modulation of apoptosis-associated genes bcl-2, bcl-x, and bax during rat liver regeneration.

AU Kren, Betsy T.; Trembley, Janeen H.; Krajewski, Stanislaw; Behrens,

Timothy W.; Reed, John C.; Steer, Clifford J. [Reprint author] CS Dep. Med., Univ. Minnesota Med. Sch., Box 36 UMHC, 516 Delaware Street SE,

Minneapolis, MN 55455, USA

SO Cell Growth and Differentiation, (1996) Vol. 7, No. 12, pp. 1633-1642.

ISSN: 1044-9523.

DT Article

LA English

ED Entered STN: 28 Jan 1997 Last Updated on STN: 28 Jan 1997

AB Liver regeneration (LR) after 70% partial hepatectomy (pH) represents a

unique in vivo model of cell cycle and gene regulation. This study was

conducted to characterize apoptosis-associated gene expression during LR.

The results indicated that transcripts for both bcl-x and bcl-2 exhibited similar patterns of expression during LR with peaks at

6 h post-PH. In contrast, the major 1.1-kb bax transcript exhibited peaks

at 18 (P lt 0.05) and 72 h (P lt 0.001) post-PH. Nuclear run-on analyses

for all three genes indicated no detectable transcription rate changes

during LR. At 6 h post-PH, when bcl-x mRNA levels were increased by

25-fold (P lt 0.001), bcl-x mRNA half-life was elevated 4-fold (P lt

0.001). Similarly, bax transcript half-life increased from 2.8 h at 0 h

to 4.3 h at 24 h (P lt 0.001) and gt 8 h at 40 h (P lt 0.001) post-PH,

coincident with increases in steady-state levels of mRNA. Western blot

analyses of Bcl-2 and Bcl-x proteins showed no significant change through 96 h of LR whereas Bax

significant change through 96 h of LR, whereas  ${\tt Bax}$  protein levels cycled

in parallel with its mRNA. Interestingly, novel Bax- and Bcl-2-cross-reactive proteins of 31 and 32 kDa, respectively, were detected in nuclei isolated from quiescent liver. When liver

induced by the peroxisome proliferator clofibrate, transcript and protein

levels were coupled for bcl-x but not for bax. In conclusion, the

apoptosis-associated genes bcl-2, bcl-x and bax are modulated at the transcript and protein levels during LR, suggesting a

role for these gene products in normal liver growth. The alterations in

transcript levels occur posttranscriptionally and involve changes in

mRNA stability. Furthermore, unlike bax, steady-state protein and transcript levels are uncoupled for both bcl-2 and bcl-x, suggesting a role for translational regulation

during
LR after PH.

L19 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

AN 1989:592378 CAPLUS

DN 111:192378

OREF 111:31935a,31938a

TI Regulation of bcl-2 gene expression in lymphoid cell lines containing normal #18 or t(14;18) chromosomes

AU Reed, John C.; Tsujimoto, Yoshihide; Epstein, Scott F.; Cuddy, Michael;

Slabiak, Trina; Nowell, Peter C.; Croce, Carlo M.

CS Sch. Med., Univ. Pennsylvania, Philadelphia, PA, 19104-6082, USA

SO Oncogene Research (1989), 4(4), 271-82 CODEN: ONCGE7; ISSN: 0890-6467

DT Journal

LA English

AB The bcl-2 (B cell lymphoma/leukemia-2) gene at band 18q21 is involved in t(14;18) chromosomal translocations in most follicular lymphomas and occasional other human B cell malignancies, where

it becomes juxtaposed to the transcriptionally active Ig (Ig) locus at

14q32. Regulation of bcl-2 gene expression was investigated in neoplastic lymphoid cell lines containing normal #18

chromosomes or a t(14;18) translocation with regard to steady-state

mRNA levels, RNA stability, transcription rates, and DNA methylation. High steady-state levels of bcl-2 mRNA, and proportionally high rates of bcl-2 transcription (measured in isolated nuclei), were found in B cell lines containing t(14;18)

translocations. The half-life of bcl-2 mRNA was similar in all cell lines examined, including a t(14;18)-containing follicular

lymphoma cell line, which has a translocated and rearranged bcl-  $^2$  gene that produces bcl- $^2$ Ig fusion

transcripts. However, in the presence of cycloheximide (inhibitor of

protein synthesis), the half-life of some of the bcl-2

/Ig mRNAs produced by these cells was prolonged, indicating that in some

circumstances mRNA stability may contribute to deregulated bcl-2 expression. Despite stabilizing some bcl-2 mRNAs, the overall effect of treating cell lines with cycloheximide was a reduction in the levels of accumulated

bcl-2 mRNAs through inhibition of bcl-

2 gene transcription. These latter data provide indirect evidence

that short-lived transacting factor(s) regulate transcription of the human

bcl-2 gene in lymphoid cells with or without a t(14;18) translocation. No clear correlation was discovered between bcl-2 gene methylation and transcription.

=> s bcl 2 alpha L20 154 BCL 2 ALPHA

=> s 120 and ARE L21 56 L20 AND ARE => dup rem 121
PROCESSING COMPLETED FOR L21

L22 36 DUP REM L21 (20 DUPLICATES REMOVED)

=> d bib abs 1-

YOU HAVE REQUESTED DATA FROM 36 ANSWERS - CONTINUE? Y/(N):y

L22 ANSWER 1 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:1116179 CAPLUS

DN 147:462499

TI Activation of melanocortin 4 receptors reduces the inflammatory response

and prevents apoptosis induced by lipopolysaccharide and interferon- $\gamma$  in astrocytes

AU Caruso, Carla; Durand, Daniela; Schioth, Helgi B.; Rey, Rodolfo; Seilicovich, Adriana; Lasaga, Mercedes

CS Centro de Investigaciones en Reproduccion, School of Medicine, University

of Buenos Aires, Buenos Aires, 1121ABG, Argent.

SO Endocrinology (2007), 148(10), 4918-4926 CODEN: ENDOAO; ISSN: 0013-7227

PB Endocrine Society

DT Journal

LA English

AB  $\alpha\text{-MSH}$  exerts an immunomodulatory action in the brain and may play a

neuroprotective role acting through melanocortin 4 receptor (MC4Rs). In

the present study, we show that MC4Rs are constitutively expressed in astrocytes as determined by immunocytochem., RT-PCR, and Western

blot anal.  $\alpha\textsc{-MSH}$  (5  $\mu M)$  reduced the nitric oxide production and the

expression of inducible nitric oxide synthase (iNOS) induced by bacterial

lipopolysaccharide (LPS, 1  $\mu g/mL$ ) plus interferon- $\gamma$  (IFN- $\gamma$ , 50 ng/mL) in cultured astrocytes after 24 h.  $\alpha$ -MSH also attenuated

the stimulatory effect of LPS/IFN- $\gamma$  on prostaglandin E2 release and

cyclooxygenase-2 (COX-2) expression. Treatment with HS 024, a selective

MC4R antagonist, blocked the antiinflammatory effects of  $\alpha\text{-MSH}$ , suggesting a MC4R-mediated mechanism in the action of this melanocortin.

In astrocytes, LPS/IFN- $\gamma$  treatment reduced cell viability, increased

the number of terminal deoxynucleotidyl transferase-mediated dUTP nick-end

labeling-pos. cells and activated caspase-3.  $\alpha\textsc{-MSH}$  prevented these

apoptotic events, and this cytoprotective effect was abolished by HS 024.

LPS/IFN- $\gamma$  decreased Bcl-2, whereas it increased Bax protein expression in astrocytes, thus increasing the Bax/Bcl-2 ratio.

 $\alpha\textsc{-MSH}$  produced a shift in Bax/Bcl-2 ratio toward astrocyte survival

because it increased Bcl-2 expression and also prevented the effect of

 $\mbox{LPS/IFN-}\gamma$  on Bax and Bcl-2 expression. In summary, these findings

suggest that  $\alpha\text{-MSH}$ , through MC4R activation, attenuates LPS/IFN- $\gamma\text{-induced}$  inflammation by decreasing iNOS and COX-2 expression and prevents LPS/IFN- $\gamma\text{-induced}$  apoptosis of astrocytes by

modulating the expression of proteins of the Bcl-2 family.

RE.CNT 54 THERE ARE 54 CITED REFERENCES AVAILABLE FOR THIS RECORD

ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 2 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:812134 CAPLUS

DN 148:97655

TI Alpha-fetoprotein-specific transfer factors downregulate alpha-fetoprotein

expression and specifically induce apoptosis in Bel7404 alpha-fetoprotein-positive hepatocarcinoma cells

AU Zhang, Hui; Bai, Zengliang; Chen, Jing; Wang, Ze; Li, Juan

CS School of Life Science, Shandong University, Jinan, Peop. Rep. China

SO Hepatology Research (2007), 37(7), 557-567 CODEN: HPRSFM; ISSN: 1386-6346

PB Blackwell Publishing Asia Pty Ltd.

DT Journal

LA English

AB Aim: To investigate the mechanisms of AFP-specific transfer factors

(AFP-TF) in induced Bel7402 cells apoptosis. Further, we investigate the

interaction between AFP-TF and AFP in the apoptosis. Methods: Bel7402 and

HepG2 AFP-pos. hepatocarcinoma cell lines, SK-Hep-1 AFP-neg. hepatocarcinoma cell line and Changliver normal liver cell line are used. Cell viability is evaluated by MTT assay and apoptosis is measured by Hoechst33342 staining and TUNEL assay. FACS is used to

analyze the cell cycle. AFP expression is examined by RT-PCR, Western

blotting and immunocytochem. The interaction between AFP-TF and AFP in

the apoptosis is investigated by addition of AFP in cultures or AFP

transfection in Bel7402 cells prior to AFP-TF treatment. Mitochondrial

membrane potential ( $\Delta \Psi m$ ) and intracellular Ca2+ concentration are resp. measured by Rhodamine123 and Fluo-3 AM Ester. Western blotting detects the involvement of several apoptosis-related proteins.

Finally, caspase-3 and Caspase-9 activity are resp. examined Results: AFP-TF can induce apoptosis in Bel7402 and HepG2 AFP-pos.

hepatocarcinoma cells, but not SK-Hep-1 and Changliver cells. AFP-mRNA

level changes little in apoptotic Bel7402 cells; while AFP expression is

downregulated and uniformly dispersed throughout the whole cell. Addition of

exogenous AFP or overexpression of intracellular AFP can reduce such

apoptotic effect. Besides, apoptotic Bel7402 cells show a disruption of

 $\Delta\Psi\text{m}\text{,}$  an immediate elevation of Ca2+ concentration, a prominently

decreased ratio of bcl-2 to bax, a release of cytochrome c from mitochondria to cytosol, and ultimately an activation of caspase-9 and

caspase-3. Conclusion: AFP-TF induced Bel7402 cells apoptosis is mitochondrial-dependent and is mediated by the interaction of AFP-TF with

intracellular AFP.

RE.CNT 28 THERE ARE 28 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 3 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1316230 CAPLUS

DN 146:200431

TI  $(\alpha/\beta+\alpha)$ -Peptide Antagonists of BH3 Domain/Bcl-xL Recognition: Toward General Strategies for Foldamer-Based Inhibition of

Protein-Protein Interactions

AU Sadowsky, Jack D.; Fairlie, W. Douglas; Hadley, Erik B.; Lee, Hee-Seung;

Umezawa, Naoki; Nikolovska-Coleska, Zaneta; Wang, Shaomeng; Huang, David

C. S.; Tomita, York; Gellman, Samuel H.

CS Department of Chemistry, University of Wisconsin, Madison, WI, 53706, USA

SO Journal of the American Chemical Society (2007), 129(1), 139-154 CODEN: JACSAT; ISSN: 0002-7863

PB American Chemical Society

DT Journal

LA English

OS CASREACT 146:200431

AB The development of mols. that bind to specific protein surface sites and

inhibit protein-protein interactions is a fundamental challenge in mol.

recognition. New strategies for approaching this challenge could have

important long-term ramifications in biol. and medicine. We are exploring the concept that unnatural oligomers with well-defined conformations ("foldamers") can mimic protein secondary structural

elements and thereby block specific protein-protein interactions. Here,

we describe the identification and anal. of helical peptide-based foldamers that bind to a specific cleft on the anti-apoptotic protein

Bcl-xL by mimicking an  $\alpha$ -helical BH3 domain. Initial studies, employing a fluorescence polarization (FP) competition assay, revealed

that among several  $\alpha/\beta$ - and  $\beta$ -peptide foldamer backbones only  $\alpha/\beta$ -peptides intended to adopt 14/15-helical secondary structure display significant binding to Bcl-xL. The most tightly binding

Bcl-xL ligands are chimeric oligomers in which an N-terminal  $\alpha/\beta$ -peptide segment is fused to a C-terminal  $\alpha$ -peptide segment ( $(\alpha/\beta+\alpha)$ -peptides). Sequence-affinity

relationships were probed via standard and nonstandard techniques (alanine

scanning and hydrophile scanning, resp.), and the results allowed us to

construct a computational model of the ligand/Bcl-xL complex. Anal.

ultracentrifugation with a high-affinity  $(\alpha/\beta+\alpha)$ -peptide established 1:1 ligand:Bcl-xL stoichiometry under FP assay conditions.

Binding selectivity studies with the most potent  $(\alpha/\beta+\alpha)$  - peptide, conducted via surface plasmon resonance measurements, revealed

that this ligand binds tightly to Bcl-w as well as to Bcl-xL, while

binding to Bcl-2 is somewhat weaker. No binding could be detected with

Mcl-1. We show that our most potent  $(\alpha/\beta+\alpha)$ -peptide can induce cytochrome C release from mitochondria, an early step in apoptosis,

in cell lysates, and that this activity is dependent upon inhibition of

protein-protein interactions involving Bcl-xL.

RE.CNT 88 THERE ARE 88 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 4 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1055893 CAPLUS

DN 143:403736

TI Activation of caspase 8 in the pituitaries of streptozotocin-induced

diabetic rats: Implication in increased apoptosis of lactotrophs

- AU Arroba, Ana I.; Frago, Laura M.; Argente, Jesus; Chowen, Julie A.
- CS Hospital Infantil Universitario Nino Jesus, Universidad Autonoma, Department of Endocrinology, Madrid, 28009, Spain
- SO Endocrinology (2005), 146(10), 4417-4424 CODEN: ENDOAO; ISSN: 0013-7227
- PB Endocrine Society
- DT Journal
- LA English
- AB Lactotroph cell death is increased in streptozotocin-induced diabetic
- rats. To determine the mechanism involved, cell death proteins were accessed
- in pituitaries of diabetic (streptozotocin at 65 mg/kg, 2 mo evolution)
- and control male rats by Western blot anal. and double immunohistochem.
- The intact and cleaved forms of caspase 9 were increased in diabetic rat
- pituitaries compared with controls. Although the proforms of caspases 3,
- 6, and 7 were increased in diabetic rat pituitaries, their activated forms
- were either unchanged or decreased. Activation of these effector caspases
- may be blocked by the increased expression of X-chromosome-linked inhibitor of apoptosis protein (XIAP) in diabetic rat pituitaries.
- However, in diabetic rats, XIAP expression in lactotrophs was decreased,
- suggesting that this cell type is not protected. Caspase 8, p53, and
- nuclear factor  $\kappa B$  were more highly activated in diabetic rat pituitaries, with caspase 8 colocalization in lactotrophs being increased.
- These results suggest that, in the pituitaries of diabetic rats, the
- cascades of normal cell turnover are partially inhibited, possibly via XIAP, and this may be cell specific. Furthermore, activation
- of the extrinsic cell-death pathway, including activation of caspase 8,
- may underlie the diabetes-associated increase in lactotroph death.
- RE.CNT 56 THERE ARE 56 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT
- L22 ANSWER 5 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN
- AN 2005:430555 CAPLUS
- DN 142:476527
- TI  $\alpha\text{-Melanocortin}$  and endothelin-1 activate antiapoptotic pathways and
  - reduce DNA damage in human melanocytes

AU Kadekaro, Ana Luisa; Kavanagh, Renny; Kanto, Hiromi; Terzieva, Silva;

Hauser, Jennifer; Kobayashi, Nobuhiko; Schwemberger, Sandy; Cornelius,

James; Babcock, George; Shertzer, Howard G.; Scott, Glynis; Abdel-Malek,

Zalfa A.

CS Department of Dermatology, University of Cincinnati College of Medicine

and Shriners' Burns Institute, Cincinnati, OH, USA

SO Cancer Research (2005), 65(10), 4292-4299 CODEN: CNREA8; ISSN: 0008-5472

PB American Association for Cancer Research

DT Journal

LA English

the

AB UV radiation is an important etiol. factor for skin cancer, including

melanoma. Constitutive pigmentation and the ability to tan are considered the main photoprotective mechanism against sun-induced carcinogenesis. Pigmentation in the skin is conferred by epidermal

melanocytes that synthesize and transfer melanin to keratinocytes.

Therefore, insuring the survival and genomic stability of epidermal

melanocytes is critical for inhibiting photocarcinogenesis, particularly

melanoma, the most deadly form of skin cancer. The paracrine factors

 $\alpha$ -melanocortin and endothelin-1 are critical for the melanogenic response of cultured human melanocytes to UV radiation. The

authors report that  $\alpha\text{-melanocortin}$  and endothelin-1 rescued human

melanocytes from UV radiation-induced apoptosis and reduced DNA photoproducts and oxidative stress. The survival effects of  $\alpha$ -melanocortin and endothelin-1 were mediated by activation of

melanocortin 1 and endothelin receptors, resp. Treatment of melanocytes

with  $\alpha\text{-melanocortin}$  and/or endothelin-1 before exposure to UV radiation activated the inositol triphosphate kinase-Akt pathway and

increased the phosphorylation and expression of the microphthalmia-related

transcription factor. Treatment with  $\alpha\text{-melanocortin}$  and/or endothelin-1 enhanced the repair of cyclobutane pyrimidine dimers and

reduced the levels of hydrogen peroxide induced by UV radiation. These

effects are expected to reduce genomic instability and mutagenesis.

## RE.CNT 49 THERE ARE 49 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 6 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:1000002 CAPLUS

DN 143:318603

TI  $\alpha$ -Tocopheryl succinate selectively induces apoptosis in neuroblastoma cells: Potential therapy of malignancies of the nervous

system?

AU Swettenham, Emma; Witting, Paul K.; Salvatore, Brian A.; Neuzil, Jiri

CS Apoptosis Research Group, School of Medical Science, Griffith University,

Southport, Queensland, Australia

SO Journal of Neurochemistry (2005), 94(5), 1448-1456 CODEN: JONRA9; ISSN: 0022-3042

PB. Blackwell Publishing Ltd.

DT Journal

LA English

AB Vitamin E (VE) analogs, epitomized by  $\alpha$ -tocopheryl succinate ( $\alpha$ -TOS), are potent inducers of apoptosis and anti-cancer agents. Here, we tested their effect on the highly malignant N-type

neuroblastoma (Nb) cells and their differentiated, neuron-like counterparts. Nb cells were highly susceptible to several VE analogs,

while differentiated Nb cells were relatively resistant to  $\alpha\text{-TOS}\,.$ 

The importance of caspase-9 rather than caspase-8, as judged by specific

siRNAs studies, together with the loss of the inner mitochondrial potential, suggests that  $\alpha\textsc{-}TOS$  triggers apoptosis in Nb cells via

the mitochondrial pathway. Cultured Nb cells were sensitized to  $\alpha\textsc{-TOS}$  by pre-treatment with Bcl-2, Bcl-xL or Mcl-1 siRNAs, while the

malignant cell line was more resistant to the vitamin E analog when Bax

was knocked down. In contrast, overexpression of Bcl-2 in Nb cells

rendered them more resistant to  $\alpha\textsc{-}TOS\textsc{-}induced$  apoptosis. The resistance of differentiated Nb cells to  $\alpha\textsc{-}TOS\textsc{-}mediated$  apoptosis

occurred via two modes: first, by up-regulation of the anti-apoptotic

Bcl-2 family proteins and second, by accumulation of decreased levels of

reactive oxygen species when challenged with  $\alpha\text{-TOS}$ . We conclude that  $\alpha\text{-TOS}$  is highly selective in killing malignant brain cancer cells while relatively inert toward differentiated neuronal cells, and

that vitamin E analogs may be novel therapeutics for the treatment of

tumors such as neuroblastomas.

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 7 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:781625 CAPLUS

DN 143:343592

TI  $\alpha 5\beta 1$  Integrin stimulates Bcl-2 expression and cell survival through Akt, focal adhesion kinase, and

Ca2+/calmodulin-dependent protein

kinase IV

AU Lee, Byung-Heon; Ruoslahti, Erkki

CS Department of Biochemistry and Research Institute for Cell & Matrix

Biology, School of Medicine, Kyungpook National University, Taegu,

700-422, S. Korea

SO Journal of Cellular Biochemistry (2005), 95(6), 1214-1223 CODEN: JCEBD5; ISSN: 0730-2312

PB Wiley-Liss, Inc.

DT Journal

LA English

AB CHO cells expressing  $\alpha 5\beta 1$  integrin are more resistant to apoptosis and express more Bcl-2 than the same cells engineered to

express  $\alpha v\beta 1$  or cytoplasmically truncated  $\alpha 5\Delta c\beta 1$  integrin as their main fibronectin receptor. The Bcl-2 up-regulation by  $\alpha 5\beta 1$  is mediated, at least in part, by the focal adhesion kinase (FAK) and phosphatidylinositol-3 kinase (PI3K)/Akt pathways. Here, we show that integrin-mediated activation of

 $\mbox{Ca2+/calmodulin-dependent}$  protein kinase (CaMK) IV, and the NF-  $\kappa B$ 

and CREB transcription factors also enhance the integrin-dependent

regulation of Bcl-2 expression in the  $\alpha 5\beta 1$  cells. A forkhead transcription factor, which is inactivated Akt, blocked Bcl-2 expression.

The FAK pathway was found to be defective in both the  $\alpha\nu\beta1$  and  $\alpha5\Delta c\beta1$  cells. These cell lines differed from one another in 2 Bcl-2-regulating pathways: adhesion through  $\alpha\nu\beta1$  failed to activate Akt, allowing forkhead to suppress Bcl-2 transcription, whereas

 $\alpha 5 \Delta c \beta 1$  did not activate NF- $\kappa B$  and CREB, presumably

because CaMK IV was not activated. Our results indicate that 3 pathways,

the FAK, PI3K/Akt, and CaMK IV mediate the survival-supporting activity of

 $\alpha$ 5 $\beta$ 1 integrin.

RE.CNT 46 THERE ARE 46 CITED REFERENCES AVAILABLE FOR THIS RECORD

## ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 8 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN DUPLICATE 1 AN 2005:235197 BIOSIS DN PREV200510021601 TI Diagnostic challenge of fetal ontogeny and its application on the ovarian teratomas. Cho, Nam Hoon [Reprint Author]; Kim, Young Tae; Lee, Ji-Hwan; AU Song, Chanil; Cho, Sung-Woo; Cho, Sang Ho; Chi, Je Geun Yonsei Univ, Coll Med, Dept Pathol, Brain Korea 21 Project Med CS Sci, Shinchon Dong 134, Seoul 120752, South Korea International Journal of Gynecological Pathology, (APR 2005) SO Vol. 24, No. 2, pp. 173-182. ISSN: 0277-1691. DTArticle LΑ English ED Entered STN: 23 Jun 2005 Last Updated on STN: 23 Jun 2005 Although neuroepithelial tubules (NET) often are a component of AB · immature teratoma (IT), they are not always required for diagnosis. Other somatic elements are sufficient and often verified with immunnohistochemical stain. This study was designed to determine the definition of immaturity versus fetal ontogeny, usinq several molecular markers in IT. It is our contention that IT is equivalent to an embryonic stage less than a fertilization age (FA) of 8 weeks, and a mature teratoma (MT) to a fetal stage later than a weeks, whereas an embryonal carcinoma (Eca) matches a pre-embryonic stage earlier than a FA of 2 weeks. The teratomatous components used as a roadmap to evaluate maturity included: a lobular structure of primitive endodermal tubules (FA 4 14 to 6 weeks), a ventricle-lined cortical plate (FA 9 weeks), a complex papillary choroid plexus (FA 10 weeks), deposition in hair follicles (FA 15 weeks), and the bell stage of odontogenesis (FA 19 weeks). The teratomatous components of 25 resected

ovarian solid teratoma samples were compared with fetal

inimuno-histochemical analysis, the CD30, CD34, CD99, bcl-

ontogeny.

For an

2, alpha-fetoprotein (AFP), and placenta-like alkaline phosphatase (PLAP) were assessed. The AFP and Ki-1 were positive in the

embryoid body, which was identified at a FA less than 4 weeks in Eca. The

AFP was positive in the primitive endodermal components and some of the

squamous epithelium in IT. The CD99 and bcl-2 were selectively stained in

the primitive NET, which was detected no later than a FA of 6 weeks. The

CD34 and bcl-2 were positive in the immature-tooking precartilage blastornatous components, which proved useful for detecting immature

cartilage, corresponding to a FA of 5 to 6 weeks. The ontogeny of IT was

found to correspond to the embryonic stage at a FA of 2 to 8 weeks, and

CD99, CD34, bcl-2, AFP, CD30, and PLAP could be used as supportive tools

to define IT. This new grading system could be more scientific and more

reproducible in any spectra of teratorna.

L22 ANSWER 9 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

AN 2005:12993 BIOSIS

DN PREV200500018187

TI Bcl-2 homodimerization involves two distinct binding surfaces, a topographic arrangement that provides an effective mechanism for Bcl-2 to

capture activated Bax.

AU Zhang, Zhi; Lapolla, Suzanne M.; Annis, Matthew G.; Truscott, Mary;

Roberts, G. Jane; Miao, Yiwei; Shao, Yuanlong; Tan, Chibing; Peng, Jun;

Johnson, Arthur E.; Zhang, Xuejun C.; Andrews, David W.; Lin, Jialing

[Reprint Author]

CS Hlth Sci CtrDept Biochem and Mol Biol, Univ Oklahoma, 940 Stanton L Young

Blvd, BMSB 935, POB 26901, Oklahoma City, OK, 73190, USA jialing-lin@ouhsc.edu

SO Journal of Biological Chemistry, (October 15 2004) Vol. 279, No. 42, pp.

43920-43928. print.

CODEN: JBCHA3. ISSN: 0021-9258.

DT Article

LA English

ED Entered STN: 22 Dec 2004 Last Updated on STN: 22 Dec 2004

AB The homo- and heterodimerization of Bcl-2 family proteins is important for

transduction and integration of apoptotic signals and control of the

permeability of mitochondria and endoplasmic reticulum membranes. Here we

mapped the interface of the Bcl-2 homodimer in a cell-free system using

site-specific photocross-linking. Bcl-2 homodimer-specific photoadducts

were detected from 11 of 17 sites studied. When modeled into the structure of Bcl-2 core, the interface is composed of two distinct

surfaces: an acceptor surface that includes the hydrophobic groove made by

helices 2 and 8 and the loop connecting helices 4 and 5 and a donor

surface that is made by helices 1-4 and the loop connecting helices 2 and

3. The two binding surfaces are on separate faces of the three-dimensional structure, explaining the formation of Bcl-2 homodimers,

homo- oligomers, and Bcl-2/Bax hetero-oligomers. We show that in vitro

the Bcl-2 dimer can still interact with activated Bax as a larger oligomer. However, formation of a Bax/Bcl-2 heterodimer is favored, since

this interaction inhibits Bcl-2 homodimerization. Our data support a

simple model mechanism by which Bcl-2 interacts with activated Bax during

apoptosis in an effective manner to neutralize the proapoptotic activity

of Bax.

L22 ANSWER 10 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN

AN 2005:505777 BIOSIS

DN PREV200510301442

TI BCL-2 alpha in human telomerized corneal epithelial cells.

AU Robertson, D. M. [Reprint Author]; Cavanagh, H. D.; Shay, J. W.; Jester,

J. V.

CS Univ Texas, SW Med Ctr, Dallas, TX 75230 USA

SO IOVS, (APR 2004) Vol. 45, No. Suppl. 1, pp. U562.

Meeting Info.: Annual Meeting of the

Association-for-Research-in-Vision-

and-Ophthalmology. Ft Lauderdale, FL, USA. April 24 -29, 2004. Assoc Res

Vis & Ophthalmol.

CODEN: IOVSDA. ISSN: 0146-0404.

DT Conference; (Meeting)

Conference; (Meeting Poster)

LA English

ED Entered STN: 23 Nov 2005

Last Updated on STN: 23 Nov 2005

AB Purpose: In the human corneal epithelium, the proto-oncogene BCL-2

exhibits a gradient pattern of expression decreasing from limbus to

central cornea and basal to superficial layer, with a loss of expression

in surface epithelial cells prior to desquamation. The purpose of this

experiment is to examine the expression of BCL-2 in a normally differentiating corneal epithelial cell line to validate this cell line as

a viable model for studying surface cell shedding in vitro. Methods:

Human Telomerized Corneal Epithelial (hTCEpi) cells immortalized with

human telomerase reverse transcriptase were grown on collagen coatedculture inserts (Corning) submerged in KGM-2 culture medium (Clonetics) containing 1.15 mM calcium for 7 days. Cells were then

air-lifted to induce differentiation and examined at day 0, 7 and 10.

Western Blotting using an anti-Keratin K3 antibody (Biogenesis) was used

to assess epithelial differentiation. Levels of Bcl-2 expression were

determined using an anti-BCL-2 monoclonal antibody (Ancell). RT PCR to

generate a 128 bp fragment crossing the intron/exon border of BCL-2 was

used to confirm the protein was splice variant alpha. Results:Consistent

with previously reported findings, following 7 days of air-lifted culture,

hTCEpi constructs differentiate in vitro similar to the human cornea in

vivo demonstrated by K3 expression. Western Blotting confirmed that the

 $26\ kD\ BCL-2$  protein is "pressed at all time points. Primers specific for

splice variant alpha confirmed that the 26 kD protein was BCL-2 alpha. Conclusions: DISCUSSION: These data suggest

that hTCEpi cells express the full length BCL-2 transcript (splice variant

alpha) containing four conserved homology domains, aregulatory loop, and a

transmembrane domain; and that the BCL-2 protein is expressed in hTCEpi

cell constructs at all stages of differentiation. These findings

are in agreement with previously reported immunohistochemistry demonstrating BCL-2 in both the normal human cornea and our hTCEpi cell

line. Taken together, these findings demonstrate a normal pattern of

BCL-2 gene expression in the hTCEpi cell line, validating it as viable

model for studying surface cell shedding in vitro.

L22 ANSWER 11 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 2

AN 2003:555263 BIOSIS

DN PREV200300558218

TI Cycloheximide and actinomycin D delay death and affect bcl-2, bax, and Ice

gene expression in astrocytes under in vitro ischemia.

AU Yu, Albert Cheung Hoi [Reprint Author]; Yung, Hon Wa; Hui, Michael Hung

Kit; Lau, Lok Ting; Chen, Xiao Qian; Collins, Richard A.

CS Department of Neurobiology, Neuroscience Research Institute, Peking

University, Peking University Health Science Center, 38 Xue Yuan Road,

Beijing, 100083, China

achy@dnachip.com.hk; achy@bjmu.edu.cn

SO Journal of Neuroscience Research, (October 15 2003) Vol. 74, No. 2, pp.

318-325. print.

ISSN: 0360-4012 (ISSN print).

DT Article

LA English

ED Entered STN: 26 Nov 2003

Last Updated on STN: 26 Nov 2003

AB An in vitro ischemia model was established and the effect of the metabolic

inhibitors cycloheximide (CHX) and actinomycin D (ActD) on apoptosis in

astrocytes under ischemia studied. CHX decreased by 75% the number of

cells dying after 6 hr of ischemia compared with control cultures.

TdT-mediated dUTP nick end labelling (TUNEL) staining of comparable

cultures was reduced by 40%. ActD decreased cell death by 60% compared

with controls. The number of TUNEL-positive cells was reduced by 38%.

The nuclear shrinkage in TUNEL-positive astrocytes in control cultures did

not occur in ActD-treated astrocytes, indicating that nuclear shrinkage

and DNA fragmentation during apoptosis are two unrelated processes. Expression of bcl-2 (alpha and

beta), bax, and Ice in astrocytes under similar ischemic conditions, as

measured by quantitative reverse transcription-polymerase chain reaction,

indicated that ischemia down-regulated bcl-2 (

alpha and beta) and bax. Ice was initially down-regulated from 0 to 4 hr, before returning to control levels after 8 hr of ischemia. ActD

decreased the expression of these genes. CHX reduced the expression of

bcl-2 (alpha and beta) but increased bax and

Ice expression. It is hypothesized that the balance of proapoptotic (Bad,

Bax) and anti-apoptotic (Bcl-2, Bcl-XI) proteins determines
apoptosis.

The data suggest that the ratio of Bcl-2/Bad in astrocytes following ActD

and CHX treatment does not decrease as much in untreated cells during

ischemia. Our data indicate that it is the ratio of Bcl-2 family members

that plays a critical role in determining ischemia-induced apoptosis. It

is also important to note that ischemia-induced apoptosis involves the

regulation of RNA and protein synthesis.

L22 ANSWER 12 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

AN 2002:829670 CAPLUS

DN 138:85054

TI Bcl-2 and Porin Follow Different Pathways of TOM-dependent Insertion into

the Mitochondrial Outer Membrane

AU Motz, Christian; Martin, Heiko; Krimmer, Thomas; Rassow, Joachim

CS Institut fur Mikrobiologie, Universitat Hohenheim,

Stuttgart-Hohenheim,

D-70593, Germany

SO Journal of Molecular Biology (2002), 323(4), 729-738 CODEN: JMOBAK; ISSN: 0022-2836

PB Elsevier Science Ltd.

DT Journal

LA English

AB The bcl-2 gene encodes a 26 kDa protein which functions as a central

regulator of apoptosis. Here we investigated the pathway of Bcl  $-2\alpha$  into the mitochondrial outer membrane using

the yeast Saccharomyces cerevisiae as a model organism. We found that

interactions of Bcl-2 $\alpha$  with the mitochondrial import receptor Tom20 are dependent on two pos.

charged lysine residues in the immediate vicinity of the carboxy-terminal

hydrophobic membrane anchor. The targeting function of these residues is

independent of Tom22. Subsequent insertion of Bcl-2.

alpha. into the mitochondrial outer membrane does not require Tom5

or Tom40, indicating that  $Bcl-2\alpha$ 

bypasses the general import pore (GIP). Bcl-2.

alpha. shows a unique pattern of interactions with the components of the mitochondrial TOM complex, demonstrating that at least two different pathways lead from the import receptor Tom20 into the mitochondrial outer membrane.

RE.CNT 53 THERE ARE 53 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 13 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN

AN 2002:368762 BIOSIS

DN PREV200200368762

TI Dynamic membrane topology of Bcl-2 during apoptosis.

AU Kim, Peter K. [Reprint author]; Annis, Matthew G. [Reprint author]; Zhu,

Weijia [Reprint author]; Falcone, Mina [Reprint author]; Leber,
Brian;

Andrews, David W. [Reprint author]

CS Biochemistry, McMaster University, 1200 Main St West, Hamilton, ON, L8NZ5,

Canada

SO FASEB Journal, (March 20, 2002) Vol. 16, No. 4, pp. A522. print. Meeting Info.: Annual Meeting of the Professional Research Scientists on

Experimental Biology. New Orleans, Louisiana, USA. April 20-24, 2002.

CODEN: FAJOEC. ISSN: 0892-6638.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

ED Entered STN: 3 Jul 2002

Last Updated on STN: 3 Jul 2002

AB Bcl-2 family proteins regulate apoptosis by multiple mechanisms including

the formation of pores. The structure of Bcl-XL resembles that of

diptheria toxin, a protein capable of forming pores in membranes. This

observation initiated our study into the pore-forming capabilities of

Bcl-2 in culture cells. The alpha5 and alpha6 helices of Bcl-2 are believed to insert into the membrane bilayer to form a pore.

To assess the conformation of Bcl-2, we examined the local environment of

cys158, located in the alpha5 helix near the base of the pore forming

region, and cys229, located in the transmembrane domain, using the

lipid-impermeant cysteine modifying agent iodoacetylamino stilbene

disulfonic acid (IASD). Only cys residues in the lipid bilayer are protected from modification by IASD. We demonstrate that cys158 of Bcl-2 is readily accessible in Rat 1 cells stably expressing

wild type Bcl-2, the mitochondrial-specific mutant or the ER-specific

mutant. However, upon induction of apoptosis cys158 is protected from

modification (and hence integrated into membranes). This is the first in

vivo evidence demonstrating the putative pore forming conformation of

Bcl-2.

L22 ANSWER 14 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2001:369365 CAPLUS

DN 135:316528

TI Protecting the myocardium from ischemic injury: A critical role for

 $\alpha$ 1-Adrenoreceptors?

AU Salvi, Sundeep

CS Department of Medicine, Southampton General Hospital, Southampton, S016

6YD, UK

SO Chest (2001), 119(4), 1242-1249 CODEN: CHETBF; ISSN: 0012-3692

PB American College of Chest Physicians

DT Journal; General Review

LA English

AB A review with 48 refs. Ischemic preconditioning (IPC) refers to the

ability of short periods of ischemia to make the myocardium more resistant

to a subsequent ischemic insult. It is the most powerful form of endogenous protection against myocardial infarction and was demonstrated

in all species evaluated to date. However, the cellular mechanisms that

drive IPC remain poorly understood. This hypothesis describes an important role for  $\alpha 1\text{-adrenoreceptors}$  in mediating IPC and discusses

the underlying mechanisms by which this is likely achieved.  $\alpha 1\text{-}Adrenoreceptors$  are present in the myocardium of all mammalian species, and several lines of evidence suggest that they play an

important role in mediating IPC. During periods of myocardial

hypoxia/ischemia, cardiomyocytes have to rely solely on anaerobic glycolysis for energy production; for this, the cells have to depend on

increased glucose entry inside the cell as well as increased glycolysis.

Stimulation of  $\alpha 1\text{-adrenoreceptors}$  increases glucose transportinside

the cardiomyocytes by translocating glucose transporter (GLUT)-1 and

GLUT-4 from the cytoplasm to the plasma membrane, enhances glycogenolysis

by activating phosphorylase kinase, increases the rate of glycolysis by

activating the enzyme phosphofructokinase, reduces intracellular acidity  $% \left( 1\right) =\left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right) \left( 1\right) +\left( 1\right) \left( 1\right)$ 

produced during excessive glycolysis by activating the Na+/H+ exchanger,

and inhibits apoptosis by increasing the levels of the antiapoptotic

protein Bcl-2. Myocardial ischemia produces an increase in the expression

of  $\alpha 1\text{-adrenoreceptors}$  in cardiomyocytes, as well as increases the

levels of its agonist norepinephrine by several fold. During ischemic

states, upregulation of  $\alpha 1$ -adrenoreceptors and increase in norepinephrine release could be a powerful adaptive mechanism that drives

IPC. An understanding into the role of  $\alpha 1$ -adrenoreceptors in mediating IPC could not only point to newer treatments for limiting

myocardial damage during myocardial infarction or heart surgery, but could

also help in avoiding the use of  $\alpha 1$ -antagonists in patients with ischemic heart disease.

RE.CNT 48 THERE ARE 48 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 15 OF 36 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights

reserved on STN

AN 2002034170 EMBASE

TI BCL2 and BAX mRNA concentration profile in fibrillary astrocytoma.

AU Mazurek, U. (correspondence); Bierzynska-Macyszyn, G.; Gola, J.; Orchel,

J.; Slowinski, J.; Wilczok, T.

CS Dept. Molec. Bio. Biochem/Biopharm., Medical University of Silesia,

Narcyzow 1 Street, Sosnowiec, Poland.

umazurek@farmant.slam.katowice.pl

SO Folia Histochemica et Cytobiologica, (2001) Vol. 39, No. SUPPL. 2, pp.

179-180. Refs: 10

ISSN: 0239-8508 CODEN: FHCYEM

CY Poland

DT Journal; Conference Article; (Conference paper)

FS 014 Radiology

016 Cancer

029 Clinical and Experimental Biochemistry

030 Clinical and Experimental Pharmacology

037 Drug Literature Index

008 Neurology and Neurosurgery

LA English

SL English

ED Entered STN: 7 Feb 2002

Last Updated on STN: 7 Feb 2002

AB A high level of the BCL2 protein and the lack of apoptosis promoting

protein BAX are beginning to be treated as markers of cellular resistance to anti-neoplastic drugs. The object of the study

specimens from stereotactic biopsy of astrocytoma fibrillare in the

central brain area, inaccessible to conventional surgery. The cytological

preparations have been evaluated with histopathological and immunohistochemical methods in order to determine the origin of the tumour

and assess cell proliferation activity. The molecular analysis conducted

in order to determine the sensitivity of the tumour to radio- or chemotherapy included the determination of the number of mRNA BCL2 alpha

and beta molecules and of BAX in 1  $\mu g$  total RNA obtained from microscope slides. A higher expression of BAX than of BCL2-alpha is a

prognosis for a positive result of chemo- or radiotherapy. A trace number

of mRNA BCL2-beta molecules and a smaller number of mRNA BCL2-alpha

molecules than mRNA BAX is a good prognosis for therapy.

L22 ANSWER 16 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN 2001:123816 BIOSIS

DN PREV200100123816

TI Effects of phenytoin on glutathione status and oxidative stress biomarker

DUPLICATE 4

gene mRNA levels in cultured precision human liver slices.

AU Gallagher, Evan P. [Reprint author]; Sheehy, Karen M.

CS Department of Physiological Sciences and Center for

Environmental and

AN

Human Toxicology, University of Florida, Gainesville, FL, 32611-0885, USA

gallaghere@mail.vetmed.ufl.edu

SO Toxicological Sciences, (January, 2001) Vol. 59, No. 1, pp. 118-126.

print.

ISSN: 1096-6080.

DT Article

LA English

ED Entered STN: 7 Mar 2001

Last Updated on STN: 15 Feb 2002

AB Cellular production of reactive oxygen species (ROS) has been implicated

as an important mechanism of chemical teratogenesis and developmental

toxicity. Unfortunately, the lack of relevant model systems has precluded

studies targeting the role of ROS in human teratogenesis and prenatal

toxicity. In the current study, we have used cultured precision human

prenatal liver slices to study the effects of the human teratogen phenytoin (diphenylhydantoin; Dilantin) on cell toxicity, glutathione

redox status, and steady-state mRNA expression of a panel of oxidative

stress-related biomarker genes. The biomarker genes analyzed were p53,

bcl-2, alpha class glutathione S-transferases

isozymes A1 and A4 (hGSTA1 and hGSTA4), and the catalytic subunit of

gamma-glutamylcysteine synthetase (gammaGCS-HS). Liver slices (200 mum)

were prepared from second trimester prenatal livers and cultured in the

presence of 0, 250 muM, and 1000 muM phenytoin for 18 h. Exposure to 1000

muM phenytoin elicited 41% and 34% reductions in slice
intracellular

potassium and reduced glutathione (GSH) concentrations, respectively. The

reduction in slice GSH concentrations at 1000 muM phenytoin was accompanied by a 2.2-fold increase in the percentage of total slice

glutathione consisting of GSSG, and a 3.9-fold increase in hGSTA1 steady-state mRNA expression. Exposure to 250 muM or 1000 muM phenytoin

also elicited a relatively minor (less than 2-fold) but significant

increase in p53 steady-state mRNA expression. In contrast, the steady-state levels of gammaGCS-HS, hGSTA4, and bcl-2 mRNAs were not

affected by phenytoin exposure. Our findings in a relevant human model

system are supportive of a protective role of GSH and hGSTA1 against phenytoin toxicity and teratogenesis. These studies also demonstrate the utility of using cultured human prenatal liver slices as a

relevant tool for developmental toxicology studies.

L22 ANSWER 17 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2000:380163 CAPLUS

DN 133:173639

TI Study of the Secondary Structure of the C-Terminal Domain of the Antiapoptotic Protein Bcl-2 and Its Interaction with Model Membranes

AU Martinez-Senac, Maria del Mar; Corbalan-Garcia, Senena; Gomez-Fernandez,

Juan C.

CS Departamento de Bioquimica y Biologia Molecular A Facultad de Veterinaria.

Universidad de Murcia, Murcia, E-30080, Spain

SO Biochemistry (2000), 39(26), 7744-7752 CODEN: BICHAW; ISSN: 0006-2960

PB American Chemical Society

DT Journal

LA English

AB Bcl-2 is a protein which inhibits programmed cell death. It is associated to

many cell membranes such as mitochondrial outer membrane,
endoplasmic

reticulum, and nuclear envelope, apparently through a C-terminal hydrophobic domain. We have used IR spectroscopy to study the secondary

structure of a synthetic peptide (a 23mer) with the same sequence as this

C-terminal domain (residues 217-239) of Bcl-2. The spectrum of this

peptide in D2O buffer shows an amide I' band with a maximum at 1622 cm-1,

which clearly indicates its tendency to aggregate in aqueous solvent. However,

the peptide incorporated in multilamellar phosphatidylcholine membranes

shows a totally different spectrum of the amide I' band, with a  $\max$  maximum at

1655 cm-1, indicating a predominantly  $\alpha\text{-helical}$  structure. Addition of

the peptide to unilamellar vesicles destabilized them and released

encapsulated carboxyfluorescein. Differential scanning calorimetry of

dimyristoylphosphatidylcholine multilamellar vesicles in which the peptide

was incorporated revealed that increasing concns. of the peptide progressively broadened the pretransition and the main transition, as is

to be expected for a membrane integral mol. Fluorescence polarization of

1,6-diphenyl-1,3,5-hexatriene in fluid phosphatidylcholine vesicles showed

that increasing concns. of the peptide produced increased polarization

values, pointing to an increase in the apparent order of the membrane and

indicating that high concns. of the peptide considerably broaden the phase

transition of dimyristoylphosphatidylcholine multilamellar vesicles.

Quenching the intrinsic fluorescence of the Tyr-235 of the peptide, by KI,

indicated that this aminoacyl residue is highly exposed to aqueous solvent

when incorporated in phospholipid vesicles. The results are discussed in terms of their relevance to the proposed topol. of insertion

of Bcl-2 into biol. membranes.

RE.CNT 80 THERE ARE 80 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 18 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 5

AN 2000:173007 BIOSIS

DN PREV200000173007

TI Gene expressions during the development and sexual differentiation of the

olfactory bulb in rats.

AU Wong, C. C. [Reprint author]; Poon, W. H.; Tsim, T. Y.; Wong, Eugene Y.

K.; Leung, M. S.

CS Department of Physiology, Chinese University of Hong Kong, Shatin, New

Territories, Hongkong, China

SO Developmental Brain Research, (Feb. 7, 2000) Vol. 119, No. 2, pp. 187-194.

print.

CODEN: DBRRDB. ISSN: 0165-3806.

DT Article

LA English

ED Entered STN: 3 May 2000 Last Updated on STN: 4 Jan 2002

AB In this study, expressions of cell-cycle-related genes: p53, retinoblastoma (Rb), p21, bcl-2alpha, bcl-2beta; protooncogene c-ski;

glial cell marker protein gene S100beta; neurotransmitter gene, substance

P and sexual-differentiation-related genes, androgen receptor (AR) and

estrogen receptor beta (ERbeta), are studied in the olfactory bulb of groups of both six female and six male rats at the ages of 3, 10,

20 and 40 days. Expressions of housekeeping genes such as beta-actin.

cyclophilin and proliferating cell nuclear antigens (PCNA) are determined using reverse transcription polymerase chain reaction (RT-PCR)

for the correction of unequal amount of cDNA added into the samples.

Using labeled 32P-dCTP and Phosphorimager technology, relative abundance

of radioactivities of the PCR products is obtained by dividing the

radioactivity of each individual sample by the corresponding radioactivities of different housekeeping genes. Data evaluated by

Two-way ANOVA indicate that only the bcl-2alpha gene expression is

affected significantly by age, sex and their interactions no matter which

of the three housekeeping genes is used for correction. When beta-actin

was used for corrections, effects of age but not sex were found in the

expressions of p53, Rb, p21, AR, ERbeta, substance P and S100beta genes,

but not in bcl-2beta, c-ski, cyclophilin and PCNA genes. While cyclophilin was used for corrections, only the p53, Rb, AR, ERbeta,

substance P and S100beta but not the bcl-2beta, p21, c-ski, PCNA and

beta-actin genes are affected by age. They are all not influenced by sex of the animals. Only the AR, ERbeta and S100beta

genes are age-dependent when PCNA was used for the correction. The other gene expressions are not altered by sex, while the interactions of age and sex were found to be significantly affecting the

bcl-2beta gene expression. Conclusively, developmental changes of the

p53, Rb, AR, ERbeta, substance P and S100beta genes expressions are quite evidenced while only the bcl-2alpha gene seems to change

significantly during the sexual differentiation of olfactory bulb in rats.

L22 ANSWER 19 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

AN 2001:71196 BIOSIS

DN PREV200100071196

TI Genes expression in the sorted Merkel cells in sinus hair follicles of the

rat.

AU Leung, M. S. [Reprint author]; Poon, W. H.; Wong, C. C.

CS Chinese Univ Hong Kong, Shatin NT, Hong Kong

SO Society for Neuroscience Abstracts, (2000) Vol. 26, No. 1-2, pp. Abstract

No.-155.4. print.

Meeting Info.: 30th Annual Meeting of the Society of Neuroscience. New

Orleans, LA, USA. November 04-09, 2000. Society for Neuroscience.

ISSN: 0190-5295.

DT Conference; (Meeting)

Conference; Abstract; (Meeting Abstract)

LA English

the

ED Entered STN: 7 Feb 2001

Last Updated on STN: 12 Feb 2002

AB Merkel cell-neurite complexes are the slowly adapting type II cutaneous mechanoreceptors. They consisted of a cluster of Merkel cells

with attachment of adjacent nerve terminals which respond to light touch

on the skin. Vibrissal hair on the face of male rats (apprx 200 gm) was

excised out for the dissection of the ring of Merkel cells from the sinus

hair follicle. The samples were loaded with quinarcrine and digested with

Dispase to dissociate the cutaneous cells. The fluorescence labeled

Merkel cells and controls (no flourescnece) were sorted out with a Coulter

Epic Altra flow cytometer into tubes with lysing buffer for subsequent RNA

extraction. The total RNA extracted were subjected to reverse transcription to get the cDNA. PCR were then carried out using 32P-labeled dCTP and specific primers for the different genes for programmed cell death and cellular signalling. In order to semi-quantitate the relative amount of mRNA for the different neuropeptides found in the Merkel cells, the amount of mRNA for

household gene beta-actin was employed to normalized the results for

different target genes. The radioactive labeled PCR products after 8%

native polyacrylamide gel electrophoresis were quantified using a phosphorimager. Programmed cell death related genes like caspace-1,

caspace3, bcl-x, BAX, BAD, CSR and calcineurin A were expressed in Merkel

and adjacent cutaneous cells; bcl-2alpha, bcl-2beta, NGFI-A and NGFI-B

were detected in Merkel cells only. Interesstingly NGFI-C was expressed

in the control cells only. For the cellular signalling related genes,

unlike most of the genes studied, ryanodine receptor type 2 genes was

expressed in control cells only.

L22 ANSWER 20 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:135058 CAPLUS

DN 130:295067

TI Nuclear localization of  $\beta$ -catenin and loss of apical brush border

actin in cystic tubules of bcl-2 -/- mice

AU Sorenson, Christine M.

CS George M. O'Brien Kidney and Urological Diseases Center, Renal Division,

Department of Medicine, Washington University School of Medicine, St.

Louis, MO, 63110, USA

SO American Journal of Physiology (1999), 276(2, Pt. 2), F210-F217 CODEN: AJPHAP; ISSN: 0002-9513

PB American Physiological Society

DT Journal

LA English

AB Tight regulation of the rates of cell proliferation and apoptosis is critical

for normal nephrogenesis. Nephrogenesis is profoundly affected by the

loss of bcl-2 expression. Bcl-2-deficient (bcl-2 -/-) mice are born with renal hypoplasia and succumb to renal failure secondary to renal

multicystic disease. Cell-cell and cell-matrix interactions impact tissue

architecture by modulating cell proliferation, migration, differentiation,

and apoptosis. E-cadherin mediates calcium-dependent homotypic cell-cell

interactions that are stabilized by its association with catenins and the actin cytoskeleton. The contribution of altered cell-cell

interactions to renal cystic disease has not been delineated. Cystic

kidneys from bcl-2 -/- mice displayed nuclear localization of  $\beta$ -catenin and loss of apical brush border actin staining. The protein levels of  $\alpha$ -catenin,  $\beta$ -catenin, actin, and E-cadherin were not altered in cystic kidneys compared with normal kidneys. Therefore, an altered distribution of  $\beta$ -catenin and actin, in

Therefore, an altered distribution of p-catenin and actin, in kidneys

from bcl-2 -/- mice, may indicate improper cell-cell interactions

interfering with renal maturation and contributing to renal cyst formation.

RE.CNT 23 THERE ARE 23 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 21 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 6

AN 1998:763358 CAPLUS

DN 130:91864

TI Cytoprotection by Bcl-2 requires the pore-forming  $\alpha 5$  and  $\alpha 6$  helixes

AU Matsuyama, Shigemi; Schendel, Sharon L.; Xie, Zhihua; Reed, John C.

CS Burnham Institute, Program on Apoptosis and Cell Death Research, La Jolla,

CA, 92037, USA

SO Journal of Biological Chemistry (1998), 273(47), 30995-31001 CODEN: JBCHA3; ISSN: 0021-9258

PB American Society for Biochemistry and Molecular Biology

DT Journal

LA English

AB We explored whether the putative channel-forming fifth and sixth  $\alpha$ -helixes of Bcl-2 and Bax account for Bcl-2-mediated cell survival

and Bax-induced cell death in mammalian cells and in the yeast Saccharomyces cerevisiae. When  $\alpha 5-\alpha 6$  were either deleted or swapped with each other, the Bcl- $2\Delta\alpha 5\alpha 6$  deletion mutant and Bcl-2-Bax( $\alpha 5\alpha 6$ ) chimeric protein failed to block apoptosis induced by either Bax or staurosporine in human cells and were unable to

prevent Bax-induced cell death in yeast, implying that the  $\alpha 5\text{-}\alpha 6$  region of Bcl-2 is essential for its cytoprotective function. Addnl. expts. indicated that, although  $\alpha 5\text{-}\alpha 6$  is necessary, it is also insufficient for the anti-apoptotic activity of

Bcl-2. In contrast, deletion or substitution of  $\alpha 5-\alpha 6$  in Bax reduced but did not abrogate apoptosis induction in human cells, whereas

it did completely nullify cytotoxic activity in yeast, implying that the

pore-forming segments of Bax are critical for conferring a lethal phenotype in yeast but not necessarily in human cells. Bax $\Delta\alpha 5\alpha 6$  and Bax- Bcl-2(.

alpha.5 $\alpha$ 6) also retained the ability to dimerize with Bcl-2. Bax therefore may have redundant mechanisms for inducing apoptosis in

mammalian cells, based on its ability to form  $\alpha 5-\alpha 6$ -dependent channels in membranes and to dimerize with and antagonize anti-apoptotic

proteins such as Bcl-2.

RE.CNT 41 THERE ARE 41 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 22 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 7

AN 1998:54978 CAPLUS

DN 128:178931

OREF 128:35275a,35278a

TI Alteration of proteins regulating apoptosis, Bcl-2, Bcl-x, Bax, Bak, Bad,

ICH-1 and CPP32, in Alzheimer's disease

AU Kitamura, Yoshihisa; Shimohama, Shun; Kamoshima, Wataru; Ota, Takashi;

Matsuoka, Yasuji; Nomura, Yasuyuki; Smith, Mark A.; Perry, George;

Whitehouse, Peter J.; Taniguchi, Takashi

CS Department of Neurobiology, Kyoto Pharmaceutical University, Kyoto, Japan

SO Brain Research (1998), 780(2), 260-269 CODEN: BRREAP; ISSN: 0006-8993

PB Elsevier Science B.V.

DT Journal

LA English

AB Recently, apoptosis has been implicated in the selective neuronal loss of

Alzheimer's disease (AD). Apoptosis is regulated by the B cell leukemia-2

gene product (Bcl-2) family (Bcl-2, Bcl-x, Bax, Bak and Bad) and the

caspase family (ICH-1 and CPP32), with apoptosis being prevented by Bcl-2

and Bcl-x, and promoted by Bax, Bak, Bad, ICH-1 and CPP32. In the present

study, we examined the levels of these proteins in the membranous and

cytosolic fractions of temporal cortex in AD and control brain. In the

membranous fraction, the levels of Bcl-2.alpha

., Bcl-xL, Bcl-x $\beta$ , Bak and Bad were increased in AD. In the cytosolic fractions, the level of Bcl-x $\beta$  was increased, while Bcl-xL,

Bax, Bak, Bad and ICH-1L were unchanged. CPP32 was not detected in AD or

control brain. These findings demonstrate a differential involvement of

cell death-regulatory proteins in AD and suggest that Bak, Bad, Bcl-2 and

Bcl-x are upregulated in AD brains.

RE.CNT 68 THERE ARE 68 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L22 ANSWER 23 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:346522 CAPLUS

DN 127:93998

OREF 127:18073a,18076a

TI Analysis of a sequenced cDNA library from multiple sclerosis lesions

AU Becker, Kevin G.; Mattson, David H.; Powers, James M.; Gado, Ameer M.;

Biddison, William E.

CS Molecular Immunology Section, Neuroimmunology Branch, National Institute

of Neurological Disorders and Stroke, National Institutes of Health,

Bethesda MD, USA

SO Journal of Neuroimmunology (1997), 77(1), 27-38 CODEN: JNRIDW; ISSN: 0165-5728

PB Elsevier

DT Journal

LA English

AB To identify genes that are expressed in MS pathogenesis, the authors have analyzed a normalized cDNA library made from mRNA obtained

from CNS lesions of a patient with primary progressive MS. Complementary

DNA clones obtained from this library were subjected to automated DNA

sequencing to generate expressed sequence tags. Anal. of this MS cDNA

library revealed the presence of 54 cDNAs that were associated with immune

activation and indicated the presence of an ongoing inflammatory response

with evidence of both cell-mediated and humoral immune responses. The

surprising finding was that 16 of the cDNAs encoded autoantigens associated

with seven other autoimmune disorders, while only three of these 16

autoantigen cDNAs were present in a similarly constructed adult brain

library. Such aberrant autoantigen expression could provide a source of

secondary autoimmune stimulation that could contribute to the ongoing

inflammatory response in MS. In addition, two cDNAs were found that mapped

to a known MS susceptibility locus (5p14-p12): one encoded an excitatory

amino acid transporter and the other a human homolog of the Drosophila

disabled gene. This approach to the mol. biol. of MS pathogenesis may

help to illuminate previously unappreciated aspects of this disease.

L22 ANSWER 24 OF 36 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights

reserved on STN

AN 1996274872 EMBASE

TI [The expanding Bcl2 gene family: Towards a comprehensive approach of the

structure/activity relationship of proteins].

L'expansion continue de la famille Bcl2. Vers une approche raisonnee des

relations structure/activite?.

AU Larsen, C.-J. (correspondence)

CS INSERM U 301, Institut de Genetique Moleculaire, 27, Rue Juliette-Dodu,

75010 Paris, France.

SO Hematologie, (1996) Vol. 2, No. 4, pp. 301-311. ISSN: 1264-7527 CODEN: HEMAF2

CY France

DT Journal; General Review; (Review)

FS 016 Cancer

022 Human Genetics

025 Hematology

LA French

SL French; English

ED Entered STN: 15 Oct 1996

Last Updated on STN: 15 Oct 1996

AB bcl2 gene is the most representative member of a growing family of genes

which counts among the main regulators of programmed cell death or

apoptosis. Some of the protein members of the family (bcl-  $2\alpha$  , bcl-x(L)) inhibit the cell death process

(subfamily 1), whereas others (bax, bak, bik) promote apoptosis (subfamily

2). These functions appear to be carried out through heterodimerization,

between members of each subfamily. Numerous works have shown that two

highly conserved domains (BH1 and BH2) are needed for heterodimerization and for biological activity. In this review, recent

data are presented on the presence of other conserved domains (BH3, NH1, NH2) that appear to be necessary for heterodimerization between

members of the BCL2 family as well as for interactions with other cellular  $\ensuremath{\mathsf{SCL}}$ 

proteins. The implication of these new features in the physiopathology of

programmed cell death in hematopoiesis and hematopoietical malignancies,

is discussed.

L22 ANSWER 25 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1995:652012 CAPLUS

DN 123:80240

OREF 123:14247a,14250a

- TI The  $\alpha 5\beta 1$  integrin supports survival of cells on fibronectin and up-regulates Bcl-2 expression
- AU Zhang, Zhuohua; Vuori, Kristiina; Reed, John C.; Ruoslahti, Erkki
- CS Cancer Res. Cent., La Jolla Cancer Res. Foundation, La Jolla,

CA, 92037,

USA

SO Proceedings of the National Academy of Sciences of the United States of

America (1995), 92(13), 6161-5

CODEN: PNASA6; ISSN: 0027-8424

PB National Academy of Sciences

DT Journal

LA English

AB Anchorage-dependent cells that are prevented from attaching to an extracellular matrix substrate stop proliferating and may undergo

apoptosis. Cell adhesion to a substrate is mediated by the integrin

family of cell surface receptors, which are known to elicit intracellular signals upon cell adhesion. We show here that Chinese

hamster ovary cells expressing the  $\alpha 5\beta 1$  integrin, which is a fibronectin receptor, do not undergo apoptosis upon serum withdrawal when

the cells are plated on fibronectin. However, the  $\alpha\nu\beta1$  integrin, which is also a fibronectin receptor and binds fibronectin on the same RGD motif as  $\alpha5\beta1$ , did not prevent apoptosis on fibronectin of the same cells. The cytoplasmic domain of the

integrin  $\alpha 5$  subunit was required for the  $\alpha 5\beta 1\text{-mediated}$  cell survival on fibronectin. The fibronectin-mediated survival effect

appeared to be independent of the level of tyrosine phosphorylation of the

focal adhesion kinase, which is induced by integrin-mediated cell attachment. The expression of the Bcl-2 protein, which counteracts

apoptosis, was elevated in cells attaching to fibronectin through  $\alpha 5\beta 1;$  cells attaching through  $\alpha \nu \beta 1$  survived only if exogenous Bcl-2 was provided. Thus,  $\alpha 5\beta 1,$  but not the closely related  $\alpha \nu \beta 1$  integrin, appears to suppress apoptotic cell death through the Bcl-2 pathway.

L22 ANSWER 26 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 8

AN 1994:299652 BIOSIS

DN PREV199497312652

TI Targeted disruption of Bcl-2-alpha-beta in mice: Occurrence of gray hair, polycystic disease, and lymphocytopenia.

AU Nakayama, Keiko; Nakayama, Kei-Ichi; Negishi, Izumi; Kuida, Keisuke; Sawa,

Hirofumi; Loh, Dennis Y.

CS Howard Hughes Med. Inst., Dep. Med. Genetics, Washington University Sch.

Med., St. Louis, MO 63110, USA

SO Proceedings of the National Academy of Sciences of the United States of

America, (1994) Vol. 91, No. 9, pp. 3700-3704.

CODEN: PNASA6. ISSN: 0027-8424.

DT Article

LA English

ED Entered STN: 13 Jul 1994 Last Updated on STN: 14 Jul 1994

AB Mice carrying ablated coding regions of the bcl-2alpha and bcl-2-beta transcripts have been made. bcl-2-/- mutants are smaller but viable, although about half of them die by 6 weeks

of age. As shown earlier with somatic bcl-2 gene-targeted mice, the

number of lymphocytes markedly decreased within few weeks after birth

while other hematopoietic lineages remained unaffected. Among lymphocytes, CD8+ T cells disappeared most quickly followed by CD4+ T

cells, whereas B cells were least affected. bcl-2-/-lymphocytes, however,

could respond normally to various stimuli including anti-CD3, Con A,

phorbol 12-myristate 13-acetate plus ionomycin, interleukin 2, lipopolysaccharide, and anti-IgM antibody. Abnormalities among nonlymphoid organs include smaller auricles, hair color turning ay at

4-5 weeks of age, and polycystic kidney disease-like change of renal

tubules. These results suggest that Bcl-2 may be involved during morphogenesis where inductive interactions between epithelium and mesenchyme are important such as in the kidneys, hair follicles, and perichondrium of auricles. Surprisingly, the nervous system, intestines, and skin appear normal despite the fact that these organs show

DUPLICATE 9

high levels of endogeneous Bcl-2 expression in normal mice.

L22 ANSWER 27 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN

1994:446674 BIOSIS

DN PREV199497459674

AN

TI The protein bcl-2-alpha does not require

membrane attachment, but two conserved domains to suppress apoptosis.

AU Borner, Christoph; Martinou, Isabelle; Mattmann, Chantal; Irmler, Martin;

Schaerer, Esther; Martinou, Jean-Claude; Tschopp, Juerg [Reprint author]

CS Inst. Biochem., Chemin des Boveresses 155, CH-1066 Epalinges, Switzerland

SO Journal of Cell Biology, (1994) Vol. 126, No. 4, pp. 1059-1068. CODEN: JCLBA3. ISSN: 0021-9525.

DT Article

LA English

ED Entered STN: 24 Oct 1994 Last Updated on STN: 24 Oct 1994

AB Bcl-2 is a mitochondrial- and perinuclear-associated protein that prolongs

the lifespan of a variety of cell types by interfering with programmed

cell death (apoptosis). Bcl-2 seems to function in an antioxidant

pathway, and it is believed that membrane attachment mediated by a

COOH-terminal hydrophobic tail is required for its full activity. To

identify critical regions in bcl-2-alpha for

subcellular localization, activity, and/or interaction with other proteins, we created, by site-directed mutagenesis, various deletion,

truncation, and point mutations. We show here that membrane attachment is

not required for the survival activity of bcl-2-

alpha. A truncation mutant of bcl-2-

alpha lacking the last 33 amino acids (T3.1) including the hydrophobic COOH terminus shows full activity in blocking apoptosis of

nerve growth factor-deprived sympathetic neurons or TNF-alpha-treated L929

fibroblasts. Confocal microscopy reveals that the T3 mutant departs into

the extremities of neurites in neurons and filopodias in fibroblasts.

Consistently, T3 is predominantly detected in the soluble fraction by

Western blotting, and is not inserted into microsomes after in vitro

transcription/translation. We further provide evidence for motifs (S-N

and S-II) at the NH-2 and COOH terminus of bcl-2, which are crucial for its activity.

L22 ANSWER 28 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 10

AN 1995:342154 BIOSIS

DN PREV199598356454

TI Dissection of functional domains in Bcl-2alpha by site-directed mutagenesis.

AU Borner, Christoph [Reprint author]; Olivier, Reynald; Martinou, Isabelle;

Martinou, Jean-Claude

CS Inst. Biochem., Univ. Fribourg, Rue du Musee 5, Perolles, CH-1700 Fribourg, Switzerland

SO Biochemistry and Cell Biology, (1994) Vol. 72, No. 11-12, pp. 463-469.

CODEN: BCBIEQ. ISSN: 0829-8211.

DT Article

LA English

ED Entered STN: 10 Aug 1995

Last Updated on STN: 10 Aug 1995

AB Bcl-2-alpha is a mitochondrial or

perinuclear-associated oncoprotein that prolongs the life span of a

variety of cell types by interfering with programmed cell death. How

Bcl-2 confers cell survival is unknown, although antioxidant and antiprotease functions have been proposed. In addition, protein structures of Bcl-2 that are crucial for its survival activity are still ill-defined. Bcl-2 can occur as Bcl-2

-alpha or Bcl-2-beta, two alternatively spliced forms which solely differ in their carboxyl termini. The finding that Bcl-2-alpha is active and membrane bound, but Bcl-2-beta is

inactive and cytosolic, indicates that the carboxyl terminus contributes

to the survival activity of Bcl-2. This region contains two subdomains, a

domain  ${\tt X}$  with unknown function and a hydrophobic stretch reported to

mediate membrane association of Bcl-2-alpha.

Recently Bcl-2-related proteins have been identified. These include Bax

that heterodimerizes with Bcl-2 and, when overxpressed, counteracts Bcl-2.

Bax contains two highly conserved regions of sequence homology with Bcl-2,

referred to as Bcl-2 homology 1 and 2 (BH1 and BH2) domains. Site-directed mutagenesis studies have revealed that both domains are not only novel dimerization motifs for the interaction of Bax with Bcl-2 but also crucial for the survival activity of Bcl-2. Interestingly, the C-terminal end of BH2 encompasses the Bcl-2-alpha/beta splice site, as well as part of domain X in Bcl-2-alpha. To better define the role of domain X and the hydrophobic C-terminal stretch of Bcl-2-alpha for its survival activity, we created various deletion and truncation mutations in these regions by site-directed mutagenesis.

We show here that membrane attachment and therefore the hydrophobic

stretch is not required for the survival activity of Bcl-2, but part of

domain X appears to be indispensable.

L22 ANSWER 29 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 11

AN 1995:124497 BIOSIS

DN PREV199598138797

TI The BCL2 gene is the prototype of a gene family that controls programmed

cell death (apoptosis).

AU Larsen, C.-J

CS INSERM U-301 SDI 159541 CNRS, Inst. Genetique Moleculaire, 27 rue J. Dodu,

75010 Paris, France

SO Annales de Genetique, (1994) Vol. 37, No. 3, pp. 121-134. CODEN: AGTQAH. ISSN: 0003-3995.

DT Article

General Review; (Literature Review)

LA French

ED Entered STN: 29 Mar 1995

Last Updated on STN: 29 Mar 1995

AB The BCL2 gene is the most representative member of a family of genes that

control cell homeostatic processes in the course of the developmental and

adult life. Some members of the BCL2 family (bcl-2-

alpha, bcl-x-L) inhibit apoptosis, whereas some others (Bax,

 $\ensuremath{\mathtt{Bclx-s}}\xspace)$  induce it. The biological activity of these proteins is dictated

by: 1) their capacity to be integrated in specific membranes of the

cytoplasm; 2) their ability to homo- or heterodimerize, due to the

presence of two highly conserved domains which are a signature of this gene family. The bcl-2 protein exhibits two main biochemical

properties: it acts in an antioxidant metabolic pathway aimed at eliminating oxygen free radicals that induce lesions in DNA, lipids and

proteins; it modulates intracellular Ca++ fluxes. BCL2 (and presumably

its congeners) interplay with other genes involved in the tight control of

cell proliferation and programmed cell death (c-myc, p53). A more

comprehensive view of BCL2 functions should benefit to cancer chemotherapy

by improving rational approach of the antitumor drug mechanisms.

L22 ANSWER 30 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN DUPLICATE 12

AN 1994:127756 BIOSIS DN PREV199497140756 TI Developmental regulation of bcl-2 expression in the thymus.

AU Moore, N. C. [Reprint author]; Anderson, G.; Williams, G. T.; Owen, J. J.

T.; Jenkinson, E. J.

CS Centre Clinical Res. Immunology Signalling, Med. Sch., Univ. Birmingham,

Birmingham B15 2TT, UK

SO Immunology, (1994) Vol. 81, No. 1, pp. 115-119. CODEN: IMMUAM. ISSN: 0019-2805.

DT Article

LA English

ED Entered STN: 24 Mar 1994

Last Updated on STN: 24 Mar 1994

AB An important factor in shaping the T-cell receptor (TcR) repertoire during

thymocyte development is the susceptibility of double-positive (CD4+ CD8+)

thymocytes to induction of apoptosis (negative selection) when the TcR is

engaged by 'self'-antigens. Recent evidence has suggested that this

susceptibility to apoptosis may be influenced by the expression of bcl-2,

a proto-oncogene known to increase the resistance to apoptosis in various

cell systems. Using a semi-quantitative polymerase chain reaction (PCR)

technique in conjunction with staged embryonic material and

thymocyte subpopulations we have investigated patterns of bcl-2 expression

during normal T-cell development. Our results show that while bcl

-2-alpha gene expression is readily detectable in

immature CD3- CD4- CD8- thymocytes and in mature single-positive TcR-hi

cells, it is drastically reduced in TcR negative double-positive (CD3-

 ${
m CD4+\ CD8+})$  cortical thymocytes of intermediate maturity. Careful mapping

of bcl-2-alpha re-expression in relation to

the onset of TcR expression within the population of embryonic thymocytes

indicates that bcl-2-alpha is up-regulated

as soon as TcR molecules are expressed on the surface of CD4+ CD8+ thymocytes. Therefore, thymocytes susceptible to apoptosis on TcR

ligation express bcl-2-alpha mRNA suggesting

that changing levels of bcl-2 expression are unlikely to be the only determinant regulating susceptibility to apoptosis in the thymus.

The possible implications of these changes in bcl-2 expression regarding

other facets of thymocyte development will be discussed.

L22 ANSWER 31 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1990:402214 CAPLUS

DN 113:2214

OREF 113:447a,450a

TI Charge configurations in oncogene products and transforming proteins

AU Karlin, Samuel; Brendel, Volker

CS Dep. Math., Stanford Univ., Stanford, CA, 94305, USA

SO Oncogene (1990), 5(1), 85-95 CODEN: ONCNES; ISSN: 0950-9232

DT Journal

LA English

AB Statistically significant charge clusters are of infrequent occurrence in all kinds of proteins. In the 6 standard classes of

protooncogene products, all of the nuclear class contain a significant

charge cluster and several, but not all, of the transmembrane class do,

whereas significant charge clusters or patterns are not found in protooncogenes of primarily cytoplasmic location, nor in membrane-bound

(src-like) protooncogenes, nor in those of the ras family. Among nuclear

oncogene families, such as myc-, jun-, fos-, myb-, or ets-related, and

among homologous proteins across species, the significant charge clusters

are part of the most conserved region. These gene families generally have similar charge distributions embodying a significant charge

cluster, not of an invariant sign, preceded by a substantial uncharged

stretch of predominantly polar residues. Nuclear transforming proteins

p53 and p68 also contain significant charge clusters together with long

uncharged segments, suggestive of a modular structure of these proteins.

Transmembrane oncogene c-mas contains a mixed charge cluster and c-fms

displays an unusual (0, +)7 pattern, in both cases positioned within their

intracellular activating domain. Distinctive charge configurations for

excreted protooncogenes are of a mixed character. Possible functions, mechanisms, and associated exptl. procedures for studying proteins

with anomalous charge distributions are discussed.

L22 ANSWER 32 OF 36 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights

reserved on STN

AN 1989273433 EMBASE

TI Stress-resistance conferred by high level of bcl-2. alpha. protein in human B lymphoblastoid cell.

AU Tsujimoto, Y.

CS The Wistar Institute of Anatomy and Biology, Philadelphia, PA 19104,

United States.

SO Oncogene, (1989) Vol. 4, No. 11, pp. 1331-1336. ISSN: 0950-9232 CODEN: ONCNES

CY United Kingdom

DT Journal; Article

FS 025 Hematology

029 Clinical and Experimental Biochemistry

LA English

SL English

ED Entered STN: 12 Dec 1991

Last Updated on STN: 12 Dec 1991

AB High levels of human bcl-2 protein(s) result in (i) the tumorgenic

conversion of mouse NIH3T3 cells, (ii) the better survival of mouse  $\$ 

myeloid cells in the absence of the required growth factor and (iii) give

a growth advantage to human EBV-lymphoblastoid B cells both in low serum

medium and limiting dilutions. The effect of the high levels of bcl-2

protein in EBV-B cells was further investigated. This revealed that high

levels of  $bcl-2\alpha$  protein made EBV-B

cells more resistant to a variety of stresses including the application of

heat shock, ethanol, methotrexate and the absence of serum. Stress

resistance was not observed in EBV-B cells with elevated level of c-myc

protein. The mechanism of stress resistance conferred by the bcl  $\mbox{-}2\alpha$  protein is yet to be determined although the

resistance does not seem to be the result of an increase in major heat

shock proteins, hsp70 and hsp90, nor the arrest of cells in G(1)/G(0)

phase. The increased viability was observed in control transfectants but

not in bcl-2 transfectants when cells are seeded at higher density in the absence of serum. Thus the improved survival of cells as a

result of high levels of the  $bcl-2\alpha$ 

protein is not specific to the absence of growth factor but is found to

occur with a variety of stresses.

L22 ANSWER 33 OF 36 CAPLUS COPYRIGHT 2008 ACS on STN AN 1988:566863 CAPLUS DN 109:166863 OREF 109:27599a,27602a TI Diagnostic methods for detecting human lymphomas associated with chromosome 14 and 18 translocations and cloning, expression, and nucleotide sequence of human bcl-2 gene IN Tsujimoto, Yoshihide; Croce, Carlos M. PA Wistar Corp., USA SO Eur. Pat. Appl., 23 pp. CODEN: EPXXDW DT Patent LA English FAN.CNT 1				
		KIND	DATE	APPLICATION NO.
DATE				
		30	10000110	TD 1007 205062
	EP 252685	A2	19880113	EP 1987-305863
19870	FP 252685	A3	19900711	
	EP 252685	B1	19930616	
				, IT, LI, LU, NL, SE
	US 5015568			US 1986-883687
19860		**		
1700.	AT 90792	Т	19930715	AT 1987-305863
19870		_		
	ES 2003064	Т3	19940901	ES 1987-305863
19870702				
	AU 8775328	A	19880218	AU 1987-75328
1987	0708			
	AU 602704	B2	19901025	
·	CA 1340827	C	19991123	CA 1987-541606
1987	0708			
	JP 63100379	A	19880502	JP 1987-172023
1987		_		770 1001 662010
	US 5202429	A	19930413	US 1991-663010
1991			10000101	TIG. 1000: 004041
	US 5595869	A	19970121	US 1992-994941
1992		70	10051017	HG 1004 220704
1004	US 5459251	A	19951017	US 1994-228704
1994		70	19960409	HC 100E 42E102
1005	US 5506344	A	19960409	US 1995-435193
1995		7\	19960604	US 1995-435181
1005	US 5523393	A	19960604	05 1995-435161
19950505 PRAI US 1986-883687 A 19860709				
LKAI	EP 1987-305863	A	19870702	
	US 1991-633010	A1	19910319	
	US 1991-663010	A1	19910319	
	09 1991-003010	VI	T > > T T O O T >	

US 1992-994941 A1 19921223 US 1994-228704 A3 19940418

AB Assays are provided for detecting a class of B-cell neoplasms associated with a chromosome translocation between chromosomes 14 and 18

which is involved in a majority of human follicular lymphomas.

One assav

uses an antibody immunoreactive with a protein overexpressed due to the

chromosome translocation. Another assay involves measurement of the amount

of mRNA which hybridizes to the gene proximal to the translocation

breakpoint. The sequences of the protein-encoding regions of the bcl-2

gene are provided as well as bacterial clones which produce the proteins. A cDNA library from poly(A) + mRNA of the pre-B-cell leukemia

line 380 was constructed and cloned into  $\lambda gt11$  phage vectors, and

recombinant clones were screened with a DNA probe consisting of a segment

of chromosome 18 which spans the hotspot of breakpoints of the translocation of chromosome 18 to chromosome 14. Three independent but

overlapping cDNA clones were obtained. The nucleotide sequences of both

strands of the 5.5- and 3.5-kilobase transcripts were determined The DNA

sequence of 5105 base pairs of the former reveals one possible open

reading frame of 239 amino acid residues (bcl-2-.

alpha.). The latter transcript codes for a 205-amino-acid residue

protein (bcl-2 $\beta$ ), differing from bcl-2. alpha. protein at the C-terminus.

L22 ANSWER 34 OF 36 EMBASE COPYRIGHT (c) 2008 Elsevier B.V. All rights

reserved on STN

AN 1988264412 EMBASE

TI Oncogenic potential of bcl-2 demonstrated by gene transfer.

AU Reed, J.C.; Cuddy, M.; Slabiak, T.; Croce, C.M.; Nowell, P.C.

CS Department of Pathology and Laboratory Medicine, University of Pennsylvania School of Medicine, Philadelphia, PA 19104-6082, United

States.

SO Nature, (1988) Vol. 336, No. 6196, pp. 259-261. ISSN: 0028-0836 CODEN: NATUAS

CY United Kingdom

DT Journal; Article

FS 016 Cancer

LA English

SL English

ED Entered STN: 11 Dec 1991

Last Updated on STN: 11 Dec 1991

AB Follicular lymphoma is the most common human B-cell malignancy in the

United States and Western Europe. Most of the tumours contain t(14;18)

chromosome translocations involving the human bcl-2 gene. Translocation

of bcl-2 sequences from chromosome 18 into the transcriptionally active

immunoglobulin locus at chromosome band 14q32 in B cells deregulates bcl-2

gene expression, resulting in the accumulation of high levels of bcl-2

messenger. Human bcl-2 transcripts generate two proteins, p26 bcl

 $-2-\alpha$  and p22 bcl-2- $\beta$ , by virtue of

alternative splice-site selection. Both proteins have in common their

first 196 NH(2)-terminal aminoacids but share little similarity with other

sequences in a data bank. Although the biological and biochemical

functions of bcl-2 are unknown, recent subcellular localization studies indicate that p26 bcl-2- $\alpha$ 

associates with cellular membranes, consistent with a stretch of hydrophobic amino acids in its carboxy terminus. The blc-2 gene may

represent a novel oncogene having no known retroviral counterpart. Here

we demonstrate the oncogenic potential of bcl-2 through a gene transfer

approach.

L22 ANSWER 35 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN 1986:437567 BIOSIS DUPLICATE 13

DN PREV198682103755; BA82:103755

TI ANALYSIS OF THE STRUCTURE TRANSCRIPTS AND PROTEIN PRODUCTS OF BCL-2 THE

GENE INVOLVED IN HUMAN FOLLICULAR LYMPHOMA.

AU TSUJIMOTO Y [Reprint author]; CROCE C M

CS WISTAR INST, 3601 SPRUCE ST, PHILADELPHIA, PA 19104, USA

SO Proceedings of the National Academy of Sciences of the United States of

America, (1986) Vol. 83, No. 14, pp. 5214-5218. CODEN: PNASA6. ISSN: 0027-8424.

DT Article

FS BA

ΑN

LA ENGLISH

ED Entered STN: 8 Nov 1986

Last Updated on STN: 8 Nov 1986

AB We have determined that the bcl-2 (B-cell leukemia/lymphoma 2) gene is

transcribed into three overlapping mRNAs, and we have cloned bcl-2 cDNA

sequences. Sequence analysis of the bcl-2 cDNA clones and comparison of

their sequences to their genomic counterparts indicate that the bcl-2 gene

contains at least two exons. The three bcl-2 transcripts, which are 8.5, 5.5, and 3.5 kilobases (kb) long, overlap within the first exon, but only the 8.5-kb and 5.5-kb transcripts contain sequences

of the second exon. The 8.5-kb and 5.5-kb transcripts seem to use

different polyadenylylation sites. Sequence analysis of the cDNA clones

corresponding to the 5.5-kb and 3.5-kb mRNAs indicates that the two bcl-2

transcripts carry two overlapping open reading frames, one of which is 717

nucleotides long and codes for a protein (bcl-2.

alpha.) of 239 amino acids and a molecular mass of 26 kDa, while the other codes for a protein of 205 amino acids (bcl-2 $\beta$ , molecular

mass 22 kDa) that is identical to bcl-2.alpha

. except at the carboxyl terminus. The bcl-2 protein products in follicular lymphomas with or without bcl-2 rearrangements are identical to the normal bcl-2 products.

L22 ANSWER 36 OF 36 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on

STN

AN 1990:50171 BIOSIS

DN PREV199089027535; BA89:27535

TI STRESS-RESISTANCE CONFERRED BY HIGH LEVEL OF BCL-2-ALPHA PROTEIN IN HUMAN B LYMPHOBLASTOID CELL.

AU TSUJIMOTO Y [Reprint author]

CS THE WISTAR INST ANAT BIOL, 3601 SPRUCE ST, PHILADELPHIA, PA 19104, USA

SO Oncogene, (1969) Vol. 4, No. 11, pp. 1331-1336. CODEN: ONCNES. ISSN: 0950-9232.

DT Article

FS BA

LA ENGLISH

ED Entered STN: 11 Jan 1990 Last Updated on STN: 11 Jan 1990

AB High levels of human bcl-2 protein(s) result in (i) the tumorigenic

conversion of mouse NIH3T3 cells, (ii) the better survival of mouse

myeloid cells in the absence of the required growth factor and (iii) give

a growth advantage to human EBV-lymphoblastoid B cells both in low serum

medium and limiting dilutions. The effect of the high levels of bcl-2

protein in EBV-B cells was further investigated. This revealed that high

levels of  $bcl-2\alpha$  protein made EBV-B

cells more resistant to a variety of stresses including the application of

heat shock, ethanol, methotrexate and the absence of serum. Stress

resistance was not observed in EBV-B cells with elevated level of c-myc

protein. The mechanism of stress resistance conferred by the bcl  $-2\alpha$  protein is yet to be determined although the

resistance does not seem to be the result of an increase in major heat

shock proteins, hsp70 and hsp90, nor the arrest of cells in G1/G0 phase.

The increased viability was observed in control transfectants but not in

high levels of the  $bcl-2\alpha$  protein is

not specific to the absence of growth factor but is found to occur with a

variety of stresses.

=> s bcl 2 alpha (3a) mRNA L23 9 BCL 2 ALPHA (3A) MRNA

=> dup rem 123

PROCESSING COMPLETED FOR L23

L24 5 DUP REM L23 (4 DUPLICATES REMOVED)

=> d bib abs 1-

YOU HAVE REQUESTED DATA FROM 5 ANSWERS - CONTINUE? Y/(N):y

L24 ANSWER 1 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 1

AN 1999:107273 CAPLUS

DN 130:148830

TI Growth hormone prevents human monocytic cells from Fas-mediated apoptosis

by up-regulating Bcl-2 expression

AU Haeffner, Astrid; Deas, Olivier; Mollereau, Bertrand; Estaquier, Jerome;

Mignon, Alexandre; Haeffner-Cavaillon, Nicole; Charpentier, Bernard;

Senik, Anna; Hirsch, Francois

CS Equipe Immunologie Cellulaire Transplantation, CNRS-UPR 420, Villejuif,

F-94801, Fr.

SO European Journal of Immunology (1999), 29(1), 334-344 CODEN: EJIMAF; ISSN: 0014-2980

PB Wiley-VCH Verlag GmbH

DT Journal

LA English

AB Apoptosis and particularly Fas-mediated apoptosis was proposed to play a

key role in controlling monocyte homeostasis. The authors and others have

documented the regulatory function of human growth hormone (hGH) on

monocytic cells, which prompted us to investigate the role of hGH on their

response to Fas antigen crosslinking. Using human promonocytic U937 cells

constitutively producing hGH upon gene transfer and human primary monocytes cultured in the presence of recombinant hGH, the authors

demonstrated that hGH diminished Fas-mediated cell death by enhancing the

expression of the antiapoptotic oncoprotein Bcl-2 as well as the level of

 $bc1-2\alpha$  mRNA. In parallel, the

authors established that overexpression of Bcl-2 through gene transfer

into normal U937 cells also diminished Fas-induced apoptosis. As a result

of Bcl-2 overexpression, the authors found that hGH greatly depressed

Fas-induced activation of the Cys protease caspase-3 (CPP32), which in

turn affected the cleavage of poly(ADP-ribose) polymerase. These data

provide evidence that hGH mediates its protective effect through a

Bcl-2-dependent pathway, clearly a crucial step in enhanced survival of

monocytic cells exposed to Fas-induced death.

RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1999:360377 CAPLUS

DN 131:183383

TI Alzheimer's disease-related gene expression in the brain of senescence

accelerated mouse

AU Wei, Xiaolong; Zhang, Yongxiang; Zhou, Jinhuang

CS Beijing Institute of Pharmacology and Toxicology, Beijing, Peop. Rep.

China

SO Neuroscience Letters (1999), 268(3), 139-142 CODEN: NELED5; ISSN: 0304-3940

PB Elsevier Science Ireland Ltd.

DT Journal

LA English

AB The levels of Alzheimer's disease (AD)-related genes, including  $\beta$ -amyloid precursor protein(APP), presentiin-1 (PS-1), PS-2, apoE,

tau, c-fos, neural cell adhesion mol. 180 (NCAM-180), TGF- $\beta$ 1, IL-1 $\alpha/\beta$ , IL-6, TNF- $\alpha/\beta$ ,  $\alpha$ -2-Macroglobulin

 $(\alpha 2M)$  , class II major histocompatibility antigen Ia (MHCII Ia), bcl-2 $\alpha$ , glucocorticoid receptor- $\alpha$  (GR $\alpha$ ) and

 ${\tt mineralocorticoid\ receptor\ (MR)\ mRNAs\ were\ determined\ by\ reverse\ transcription}$ 

polymerase chain reaction (RT-PCR) in the hippocampus and cerebral cortex

of senescence accelerated mouse (SAM). The levels of TGF- $\beta$ 1, IL-1 $\alpha$ , TNF- $\beta$ , c-fos, NCAM-180, PS-1 and APP mRNAs were normally expressed in SAMP8 compared with age-matched other subline that

resistant (SAMR1). The levels of apoE, GR $\alpha$  and MR mRNAs in the hippocampus of SAMP8, especially GR $\alpha$ , were evidently lower than those in

the hippocampus of SAMR1. While bcl-2 $\alpha$ , PS-2 and tau mRNA levels of

SAMP8 were significantly higher than those of SAMR1.

Inflammatory

is

cytokines (IL-1 $\beta$ , IL-6, TNF- $\alpha$ ),  $\alpha$ 2M and MHCII Ia antigen mRNAs were not detected in the brain of SAM. The differences of gene

expression in the cerebral cortex were less evident than in the hippocampus. The results indicated that some genes abnormally expressed

in the AD brain were also found in the brain of SAMP8, which may contribute to its age-related deterioration of learning and emory. The

authors' results also suggested that functional and pathol. changes which

occurred in the brain of SAMP8 possessed some different aspects in

comparison with the AD in consideration of the differences in gene

expression.

RE.CNT 20 THERE ARE 20 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 3 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1996:647522 CAPLUS

DN 125:272311

OREF 125:50873a,50876a Apoptosis and expression of bcl-2  $\alpha$  , TI mRNA isoforms and protein in neuroblastoma Mazzocco, K.; Scaruffi, P.; Gambini, C.; Negri, F.; Tonini, G. P. ΑU Advanced Biotechnology Center, G. Gaslini Institute, Genoa, CS 16132, Italy Apoptosis (1996), 1(1), 63-68 SO CODEN: APOPFN; ISSN: 1360-8185 Rapid Science Publishers PΒ DTJournal LΑ English The authors studied apoptosis in 36 neuroblastomas by DNA ladder AB assay. Expression of bcl-2 $\alpha$  and  $\beta$ mRNA isoforms and protein were detected by RT-PCR and by immunohistochem., resp. Internucleosomal DNA fragmentation was found in 20/36 (56%) tumor tissues collected both at onset and relapse of disease. Bcl-2 $\alpha$  and  $\beta$  mRNAs and protein were found in almost all examined tumors irresp. of DNA ladder, thus showing lack of correlation with the clin. stage. BCL-2 protein was observed to be expressed at various levels in undifferentiated and in more differentiated neuroblasts, while the stroma and the fibrovascular tissue were neg. The results show that apoptosis is present in neuroblastoma at all stages and that bcl-2 gene is widely expressed in tumor tissue. In this series of neuroblastomas, bcl-2 expression was not correlated with unfavorable prognosis. BIOSIS COPYRIGHT (c) 2008 The Thomson ANSWER 4 OF 5 Corporation on STN DUPLICATE 2 1994:127756 BIOSIS AN PREV199497140756 DNDevelopmental regulation of bcl-2 expression in the thymus. TI Moore, N. C. [Reprint author]; Anderson, G.; Williams, G. T.; ΑU Owen, J. J. T.; Jenkinson, E. J. Centre Clinical Res. Immunology Signalling, Med. Sch., Univ. CS Birmingham, Birmingham B15 2TT, UK Immunology, (1994) Vol. 81, No. 1, pp. 115-119. SO CODEN: IMMUAM. ISSN: 0019-2805. DTArticle

LΑ

ED

English

Entered STN: 24 Mar 1994

Last Updated on STN: 24 Mar 1994

AB An important factor in shaping the T-cell receptor (TcR) repertoire during

thymocyte development is the susceptibility of double-positive (CD4+ CD8+)

thymocytes to induction of apoptosis (negative selection) when

engaged by 'self'-antigens. Recent evidence has suggested that this

susceptibility to apoptosis may be influenced by the expression of bcl-2,

a proto-oncogene known to increase the resistance to apoptosis in various

cell systems. Using a semi-quantitative polymerase chain reaction (PCR)

technique in conjunction with staged embryonic material and purified

thymocyte subpopulations we have investigated patterns of bcl-2 expression

during normal T-cell development. Our results show that while bcl-2-alpha

gene expression is readily detectable in immature CD3- CD4- CD8thymocytes and in mature single-positive TcR-hi cells, it is drastically

reduced in TcR negative double-positive (CD3- CD4+ CD8+) cortical thymocytes of intermediate maturity. Careful mapping of bcl-2-alpha

re-expression in relation to the onset of TcR expression within the

population of embryonic thymocytes indicates that bcl-2-alpha is up-regulated as soon as TcR molecules are expressed on the surface of CD4+

 $\ensuremath{\texttt{CD8+}}$  thymocytes. Therefore, thymocytes susceptible to apoptosis on  $\ensuremath{\texttt{TCR}}$ 

ligation express bcl-2-alpha mRNA

suggesting that changing levels of bcl-2 expression are unlikely to be the

only determinant regulating susceptibility to apoptosis in the thymus.

The possible implications of these changes in bcl-2 expression regarding

other facets of thymocyte development will be discussed.

L24 ANSWER 5 OF 5 CAPLUS COPYRIGHT 2008 ACS on STN DUPLICATE 3

AN 1993:252039 CAPLUS

DN 118:252039

OREF 118:43710h,43711a

TI The bcl-2 gene is highly expressed during neurogenesis in the central

nervous system

AU Abe-Dohmae, Sumiko; Harada, Nobuhiro; Yamada, Kazuyo; Tanaka, Ryo CS Med. Sch., Nagoya City Univ., Nagoya, 468, Japan

SO Biochemical and Biophysical Research Communications (1993), 191(3), 915-21

CODEN: BBRCA9; ISSN: 0006-291X

DT Journal

LA English

AB An anal. method for quantitation of the RNA transcripts of murine bcl-2

gene was developed. The PCR products from bcl-2 $\alpha$  and bcl-2 $\beta$  mRNA were fluorometrically analyzed and their specific contents were

calculated by the internal standard method. Both bcl-2 mRNAs in adult mice were

transcribed at the highest level in the thymus and at a comparable level

in the spleen. Aside from the immune system, the brain gave the most

abundant levels of the bcl-2 mRNAs. The ratios of bcl-2  $\beta$  mRNA to bcl-2  $\alpha$  mRNA

in the thymus and spleen were significantly higher than those in other

tissues. During development of the brain, the bcl-2 $\alpha$  and bcl-2 $\beta$  mRNA levels were highest on embryonic day 15, and about two

and three times higher than those of adult, resp. The results suggest

that the bcl-2 gene functions to regulate development and survival of

neurons in the central nervous system.

=> s 3 UTR and bcl 2

L25 69 3 UTR AND BCL 2

=> s 125 and PY<=1998

L26 8 L25 AND PY<=1998

=> dup rem 126

PROCESSING COMPLETED FOR L26

L27 4 DUP REM L26 (4 DUPLICATES REMOVED)

=> d bib abs 1-

YOU HAVE REQUESTED DATA FROM 4 ANSWERS - CONTINUE? Y/(N):y

L27 ANSWER 1 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1998:672675 CAPLUS

DN 129:271496

OREF 129:55245a,55248a

TI Viral vectors for identification of RNA regulatory sequences and interacting molecules

IN Blau, Helen M.; Spicher, Albert; Guicherit, Oivin

PA The Board of Trustees of the Leland Stanford Junior University, USA

SO PCT Int. Appl., 64 pp.

CODEN: PIXXD2

DTPatent

LΑ English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO.

DATE

----\_\_\_\_\_\_

PI WO 9842854 A1 19981001 WO 1998-US6093

19980327 <--

W: CA, JP

RW: AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

19970327 PRAI US 1997-42543P P

Methods and compns. for the identification, characterization and isolation

of regulatory RNA sequences are provided. Regulatory RNA sequences

mediate post-transcriptional regulation in response to various environmental conditions and can be used to alter the level of

of endogenous genes or to identify factors which interact with

RNA sequences. The invention addnl. provides improved vector systems for

rapid screening, anal., and tightly-regulated expression of regulatory RNA

sequences. The regulatory properties of highly conserved regions (HCRs)

within 3'-UTRs that have retained greater than 70% homol. within stretches

of 100 nucleotides over 30 million years were examined A retroviral vector

system was used with a selectable marker that allowed rapid delivery of

3'-UTR-reporter constructs to populations of thousands

of cells within one to two weeks, avoiding problems associated with clonal

anal. and long-term selection. Addnl., this vector is modular,

permitting direct comparison of different HCRs on gene expression,

independent of 5'-UTRs, promoters, protein coding regions and polyadenylation signals. Ten HCRs (from c-fos, c-myc, transferrin

receptor, bcl2,  $EFl\alpha$ , vimentin, ornithine decarboxylase, fibronectin, HuD and Ran genes) were examined Nine of these HCRs (i.e., all

except the Ran HCR) were found to decrease mRNA stability to different

Two HCRs (the c-fos and vimentin HCRs) altered mRNA extents. translation

under steady-state conditions. Four HCRs (the HuD, Ran, fibronectin and

ornithine decarboxylase HCRs) mediated responses to changes in mitogen

level by increasing reporter protein levels 2-fold while 2 HCRs exhibited

a 6-fold difference in their response to another environmental stress,

hypoxia.

RE.CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 2 OF 4 CAPLUS COPYRIGHT 2008 ACS on STN

AN 1997:607952 CAPLUS

DN 127:303779

OREF 127:59271a,59274a

TI Rapid molecular cloning of rearrangements of the IGHJ locus using long-distance inverse polymerase chain reaction

AU Willis, T. G.; Jadayel, D. M.; Coignet, L. J. A.; Abdul-Rauf, M.; Treleaven, J. G.; Catovsky, D.; Dyer, M. J. S.

CS Academic Department of Haematology and Cytogenetics, Haddow Laboratories,

Institute of Cancer Research-Royal Marsden Hospital, Surrey, SM2 5NG, UK

SO Blood (1997), 90(6), 2456-2464 CODEN: BLOOAW; ISSN: 0006-4971

PB Saunders

DT Journal

LA English

AB Clonal rearrangements of the Ig heavy chain (IGH) locus consisting of

either intrachromosomal VDJ rearrangements or interchromosomal translocations are a consistent feature of all B-cell malignancies and may

be used both diagnostically and to monitor response to therapy. Many of

these rearrangements are targeted to the IGHJ segments, but only some can

be amplified with regular polymerase chain reaction (PCR) techniques. To

permit PCR amplification of potentially all IGHJ rearrangements, we have

devised a method incorporating self-ligation of restriction endonuclease-digested DNA fragments with long-distance PCR (long-distance,

inverse PCR [LDI-PCR]). We show here, using only 4 nested oligonucleotide

primers, the successful amplification and DNA sequencing of all IGHJ

rearrangements up to 5.4 kb in length from a panel of 13 cases and cell

lines of various types of B-cell malignancy. In all cases, both VDJ and

DJ IGH rearrangements and translocation breakpoints were amplified. Six

cases exhibited t(14;18)(q32;q21). All translocation breakpoints were

cloned and sequenced. Three cases exhibited a rearrangement to the BCL2

major breakpoint region (MBR). However, 2 other cases exhibited rearrangements between the MBR and the minor cluster region (mcr). These

2 cases broke within 44 bp of each other, confirming the presence of an

addnl. 3' BCL2 breakpoint cluster region. The final case fell immediately

3' of the 3' UTR of the BCL2 gene adjacent to an Alu

repeat. No other BCL2 breakpoints within this region have been reported.

Four cases exhibited t(11;14)(q13;q32). All 3 cases with translocations

targeted to the IGHJ segments were successfully amplified and sequenced,

including 1 case in which the BCL1 translocation could not be detected by

DNA blot using the currently available probes. All three translocation

breakpoints fell outside the BCL1 major translocation cluster between 20

and 40 kb telomeric and showed no clustering. Two of the three fell

within or adjacent to Alu repeat regions. LDI-PCR is a simple and robust

technique that allows PCR amplification of nearly all IGHJ rearrangements.

RE.CNT 45 THERE ARE 45 CITED REFERENCES AVAILABLE FOR THIS RECORD ALL CITATIONS AVAILABLE IN THE RE FORMAT

L27 ANSWER 3 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson Corporation on STN

DUPLICATE 1

AN 1997:69518 BIOSIS

DN PREV199799368721

TI Cloning of the 3' end of rat bax-alpha and corresponding developmental

down-regulation in differentiating primary, cultured oligodendrocytes.

AU Madison, Dana L. [Reprint author]; Pfeiffer, Steven E.

CS Dep. Microbiol., MC-3205, University of Connecticut Sch. Med., Farmington,

CT 06030, USA

SO Neuroscience Letters, (1996) Vol. 220, No. 3, pp. 183-186. CODEN: NELED5. ISSN: 0304-3940.

DT Article

LA English

```
OS
    Genbank-U59184
ED
    Entered STN: 11 Feb 1997
     Last Updated on STN: 25 Mar 1997
     Bax-alpha is thought to form heterodimers with Bcl-2
AB
     and prevent apoptotic cell death. A sequence was isolated from
     oligodendrocyte cDNA corresponding to the uncloned 3' end of the
rat
     bax-alpha coding region and part of the 3' UTR via a
     degenerate polymerase chain reaction (PCR)-based cloning method.
 The rat
     bax-alpha clone is 96 and 91% homologous to mouse and human
clones,
     respectively, and the 3' UTR demonstrates high
     homology with the cloned human 3' UTR. Northern
     analysis demonstrated that the 1.0 kb bax-alpha mRNA species was
     predominant. bax-alpha mRNA is expressed in mitotic,
oligodendrocyte
     progenitors, and is subsequently down-regulated 2-fold in
differentiating
     oligodendrocytes.
    ANSWER 4 OF 4 BIOSIS COPYRIGHT (c) 2008 The Thomson
L27
Corporation on STN
     DUPLICATE 2
AN
     1996:414837 BIOSIS
DN
     PREV199699137193
     A bcl-2/IgH antisense transcript deregulates
TI
     bcl-2 gene expression in human follicular lymphoma
     t(14;18) cell lines.
     Capaccioli, S.; Quattrone, A.; Schiavone, N.; Calastretti, A.;
ΑU
Copreni,
     E.; Bevilacqua, A.; Canti, G.; Gong, L.; Morelli, S.; Nicolin,
A. [Reprint
     author]
     Dep. Pharmacol., Sch. Med., Via Vanvitelli 32, 20129 Milan, Italy
CS
     Oncogene, (1996) Vol. 13, No. 1, pp. 105-115.
SO
     CODEN: ONCNES. ISSN: 0950-9232.
     Article
DT
LA
     English
     Entered STN: 10 Sep 1996
ED
     Last Updated on STN: 10 Sep 1996
     The 14;18 chromosome translocation, characteristic of most human
AB
     follicular B-cell lymphomas, juxtaposes the bcl-2 gene
     with the IgH locus, creating a bcl-2/IgH hybrid gene.
     By mechanisms that are still under investigation, this event
increases the
     cellular levels of the bcl-2 mRNA and thereby induces
     an overproduction of the antiapoptotic BCL-2 protein
     which is likely responsible for neoplastic transformation.
                                                                  In
an effort
     to identify potential upregulators of bcl-2 activity
     in t(14;18) cells, we found, by strand-specific RT-PCR, a hcl-2
antisense
```

transcript that is present in the t(14;18) DOHH2 and SU-DHL-4 but not in

the t(14;18)-negative Raji and Jurkat lymphoid cell lines, and thus

appears to be dependent on the bcl-2/IgH fusion. This antisense transcript is a hybrid bcl-2/IgH RNA, that originates in the IgH locus, encompasses the t(14;18) fusion site and

spans at least the complete 3' UTR region of the bcl-2 mRNA. To achieve some insight into its biological function, we treated the t(14;18) DOHH2 cell line with oligonucleotides

(ODNs) by specifically targeting the bcl-2/IgH antisense strand. These ODNs lowered bcl-2 gene expression, inhibited neoplastic cell growth by inducing apoptosis. We

would like to propose the hypothesis that the bcl-2 /IgH antisense transcript may contribute, by an unknown mechanism, to

upregulation of bcl-2 gene expression in t(14;18) cells. The possibility has been considered that the hybrid antisense

transcript mask AU-rich motifs present in the 3' UTR of the bcl-2 mRNA characterized in other genes as mRNA destabilizing elements.

=>

---Logging off of STN---

=>

Executing the logoff script...

=> LOG Y

COST IN U.S. DOLLARS

SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE

-20.00

-27.20

STN INTERNATIONAL LOGOFF AT 16:28:40 ON 02 SEP 2008

```
Welcome to STN International! Enter x:x
```

LOGINID: ssspta1633cxq

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

```
Welcome to STN International
NEWS
      1
                 Web Page for STN Seminar Schedule - N. America
NEWS 2 APR 04
                 STN AnaVist, Version 1, to be discontinued
NEWS
      3 APR 15
                 WPIDS, WPINDEX, and WPIX enhanced with new
                 predefined hit display formats
NEWS 4 APR 28
                 EMBASE Controlled Term thesaurus enhanced
NEWS 5 APR 28
                 IMSRESEARCH reloaded with enhancements
NEWS 6 MAY 30
                 INPAFAMDB now available on STN for patent family
                 searching
NEWS
      7 MAY 30
                 DGENE, PCTGEN, and USGENE enhanced with new homology
                 sequence search option
NEWS
         JUN 06
                 EPFULL enhanced with 260,000 English abstracts
NEWS 9
         JUN 06
                 KOREAPAT updated with 41,000 documents
NEWS 10
         JUN 13
                 USPATFULL and USPAT2 updated with 11-character
                 patent numbers for U.S. applications
                 CAS REGISTRY includes selected substances from
NEWS 11
        JUN 19
                 web-based collections
NEWS 12
         JUN 25
                 CA/CAplus and USPAT databases updated with IPC
                 reclassification data
NEWS 13
         JUN 30
                 AEROSPACE enhanced with more than 1 million U.S.
                 patent records
NEWS 14
         JUN 30
                 EMBASE, EMBAL, and LEMBASE updated with additional
                 options to display authors and affiliated
                 organizations
NEWS 15
         JUN 30
                 STN on the Web enhanced with new STN AnaVist
                 Assistant and BLAST plug-in
                 STN AnaVist enhanced with database content from
NEWS 16
         JUN 30
EPFULL
NEWS 17
         JUL 28
                 CA/CAplus patent coverage enhanced
NEWS 18
         JUL 28
                 EPFULL enhanced with additional legal status
                 information from the epoline Register
NEWS 19
         JUL 28
                 IFICDB, IFIPAT, and IFIUDB reloaded with
enhancements
         JUL 28
NEWS 20
                 STN Viewer performance improved
NEWS 21 AUG 01
                 INPADOCDB and INPAFAMDB coverage enhanced
NEWS 22 AUG 13
                 CA/CAplus enhanced with printed Chemical Abstracts
                 page images from 1967-1998
```